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ABSTRACT 
 
Pheochromocytoma and paraganglioma are tumors of chromaffin cells occurring 
within the adrenal medulla or the sympathetic nervous system, respectively. About 15% 
of these tumors are malignant, especially in patients with mutations in the subunit B of 
the succinate dehydrogenase, who have a 40% probability of developing distant 
metastases. For these malignancies surgery is currently the treatment of choice, but, 
especially for advanced forms, treatment is unsatisfactory and prognosis is very poor. 
Thus, novel treatment options for these patients are urgently in need. Recent advances in 
our understanding of the molecular pathology of pheochromocytoma and paraganglioma 
have led to the identification of key oncogenic events. Several molecular pathways have 
been suggested to play a role in these tumors, including the RTKs/Ras/MAPK, 
PI3K/Akt/mTOR, HIF, HSP90 and mithocondrial proteins involved in energy-producing 
pathways. This increased knowledge can be matched by the increased number of novel 
compounds, including tyrosine kinase inhibitors and other novel targeted therapies 
already in clinical trial for other cancers, targeting signaling pathways important for 
tumor proliferation, survival and metastatic dissemination.  
The overarching objective of this research project was to identify mechanism-based, 
molecularly targeted therapeutic approaches to modulate cancer cell growth and 
metastatic growth in pheochromocytoma, promoting the translational development of 
more effective therapeutic options for these tumors. The lack of sensitive animal models 
of pheochromocytoma has hindered the study of this tumor and in vivo evaluation of 
antitumor agents.To this end, two in vivo models for the evaluation of efficacy of several 
molecular targeted therapies were developed: an experimental metastasis model to 
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monitor tumor spreading and a subcutaneous model to monitor tumor growth and 
spontaneous metastasis. These models offer a platform for sensitive, non-invasive and 
real-time monitoring of pheochromocytoma primary growth and metastatic burden to 
follow the course of tumor progression and for testing relevant antitumor treatments in 
metastatic pheochromocytoma. 
I then use in vitro experiments and the in vivo models above described to test the 
efficacy of selective ATP-competitive inhibitors targeting both mTORC1 and mTORC2 
complexes, pointing out an important role for the mTOR signaling pathway in the 
development of pheochromocytoma. 
Moreover, I investigated also the 90 kDa heat shock protein (Hsp90) as a potential 
therapeutic target for advanced pheochromocytoma, using both first and second 
generation Hsp90 inhibitors. 
As an alternative approach to identify potential drugs that can more rapidly be 
implemented into clinical trials in patients with metastatic pheochromocytoma or 
paraganglioma, I used a drug repurposing/repositioning approach. With this strategy, 
several molecules with potential bioactivity in pheochromocytoma cells were identified, 
including an example of a combination with synergistic effect. 
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1.1 The adrenal gland and paraganglia. 
The adrenal glands (or suprarenal gland) are bilateral triangular organs located in the 
retroperitoneal space and lying on the superior pole of the kidney. The adrenal glands are 
major endocrine glands in mammals. They are mainly involved in the physiological 
response to stress by producing and secreting steroid hormones and catecholamines 
Each adrenal grand is divided into two distinct areas: the outer cortex and the inner 
medulla. It is important to note that these two parts have a distinct embryological origin, 
structure and functions. Briefly, the adrenal cortex is further subdivided into three areas 
synthetizing and secreting several steroidal hormones. From the external surface these 
areas are: the zona glomerulosa (which produce the mineralcorticoid aldosterone), the 
zona fasciculata (which produce mainly the glucocorticoid cortisol) and the zona 
reticularis (which produce mainly the androgens, including testosterone). 
The adrenal medulla is located in the center of the adrenal gland and represents only  
around 10% of the adrenal total weight. During embryogenesis, neuroblasts from the 
neural crest migrate to the medial side of the fetal adrenal cortex and, over time, these 
cells are mantled by the surrounding fetal cortex. These cells eventually differentiate into 
chromaffin cells (sometimes referred as pheochromocytes), so called because the 
granules inside the cells stains yellow-brown when exposed to chromium salts (affinity to 
chromium): specifically chromium salts oxidize and polymerize cathecolamines which 
stain in the mentioned colors. Chromaffin cells are structurally similar to postsynaptic 
sympathetic neurons, and, similarly to the secretory hypothalamic neurons in the brain, 
release hormones directly into the systemic circulation. Outside the adrenal medulla, 
chromaffin cells can also be found in the sympathetic ganglia, paraganglia, in proximity 
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of the carotid body, the organ of Zuckerkandl (which contain the largest number of 
extraadrenal chromaffin cells in humans), and in small amount also in the wall of the 
bladder and the prostate. In margin, the enterochromaffin cells are distinct cells which 
only share a similar staining pattern but their function and embryological origin is 
different from the adrenal medulla chromaffin cells. 
Chromaffin cells in the adrenal medulla make contact with presynaptic sympathetic 
ganglia of the sympathetic nervous system, representing collectively as the 
sympathoadrenal system. Chromaffin cells secretes three main types of cathecolamines: 
epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine. 
 
1.2 Pheochromocytoma and paraganglioma 
Pheochromocytoma is a rare catecholamine-producing neuroendocrine tumor derived 
from the chromaffin cells in the adrenal medulla [1] [2]. The embryological origin of 
these cells from the neural crest outlines the peculiar development and pathogenesis of 
these tumors. Catecholamine producing tumors arising from extra-adrenal cells are 
known as paragangliomas. These tumors share overlapping characteristics that span 
histopathology, epidemiology, and even molecular pathobiology, but also many 
differences in terms of their behavior, aggressiveness and metastatic potential, and they 
can be either sporadic or be present in multiple members of the same family [3] [4].  
 
The study of familial syndromes of pheochromocytoma has been very important in 
understanding the pathogenic mechanisms involved in both familial as well as sporadic 
forms. Several susceptibility genes have been established as playing a central role in the 
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pathogenesis of both pheochromocytomas and paragangliomas [5] [6].. At the moment 
ten different genes have been implicated in the pathogenesis of these tumors: the von 
Hippel-Lindau (VHL) tumor suppressor gene, the Rearranged during transfection (RET) 
protooncogene, the neurofibromatosis type 1 (NF1) tumor suppressor gene, genes 
encoding for four subunit (A, B, C and D) of the succinate dehydrogenase (SDH) 
complex, a gene encoding for an enzyme responsible for flavination of the SDHA subunit 
(SDHAF2), and finally the genes TMEM127 and the MAX which have been recently 
described [7].. Genetic studies suggest that other genes may be involved in the 
pathogenesis of these tumors and investigations are under way to uncover novel 
mutations in “sporadic” cases. Extensive use of genetic analysis as common practice in 
the clinic, has significantly extended the number of patients identified to have genetic 
predisposition to pheochromocytoma and paraganglioma. Indeed, the old “rule of 10” to 
describe the percentage of patient with genetic disease is clearly outdated and now at 
least 25% of “sporadic” patients have been found to have genetic mutations in one of the 
genes mentioned above. The proteins encoded by these genes are involved in several 
cellular pathways. The detailed and thorough dissection of the molecular pathways will 
help to better understand the pathogenic mechanisms underlying the disease and to 
identify novel key molecules to be used for targeted molecular therapy, for diagnostic and 
prognostic purposes. 
According to more recent publications, up to 30-32 % of these tumors are genetically 
inherited [8] and it is estimated that this number will rise in the future when new 
susceptibility genes will be discovered. Indeed, it is generally accepted that certain 
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susceptibility genes yet to be discovered may not ‘at first look’ seem to run in families 
due to their very low penetrance inspite of passing down several generations. 
Hereditary pheochromocytomas and paragangliomas can be divided into two clusters 
based on transcription profile revealed by microarray analysis. One cluster is the tumors 
with VHL and SDHx  mutant genes and the other cluster contains tumors with RET and 
NF1 mutant genes [9,10]. Sporadic tumors were surprisingly represented in both clusters. 
As newer genes were discovered further microarray studies tried to classify them into 
these two clusters and mutations in KIF1Bbeta, TMEM127 and MAX clustered with 
RET/NF1 and SDHAF2 and SDHA clustered with SDHx/VHL [11]. 
In the following discussion, we are briefly summarizing the current knowledge on the 
susceptibility genes in these two clusters. 
 
1.3 Susceptibility genes and molecular pathways: the gateway to a better 
understanding of the pathophysiology of pheochromocytoma. 
1.3.1 The VHL and SDH clusters 
In the past a link between high altitude chronic hypoxia and an increased prevalence of 
hyperplasia of the carotid bodies as well as a higher prevalence of paragangliomas 
compared to those living at sea level has been observed. This association and the fact that 
the carotid body plays a central role in oxygen sensing made researchers believe that 
oxygen sensing might play a role in the tumorigenesis of paragangliomas [12]. The basis 
underlying this association seems to be confirmed with the pseudohypoxia hypothesis for 
tumorigenesis caused due to VHL and SDHx mutations. Mutations in these genes lead to 
accumulation and stablization of hypoxia inducible factor alpha. Hypoxia Inducible 
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Factor alpha (HIF) heterodimerizes with HIF beta and acts as an active transcription 
factor which induces a variety of genes involved in cellular and tissular adaptation to 
hypoxia (angiogenesis, metabolism and survival). The HIF alpha is hydroxylated by 
prolyl hydroxylases (more specifically EGLN1) under normoxic conditions into 
hydroxylated HIF alpha. This is recognized by the VHL protein and marked for 
degradation in the proteasome. If the VHL gene is mutated the protein is not formed and 
HIF alpha cannot be degraded and it accumulates. Succinate dehydrogenase enzymes 
convert succinate to fumarate and its mutation leads to accumulation of succinate. 
Succinate is a competitive inhibitor of the prolyl hydroxylase EGLN1 and leads to 
accumulation of stable HIF alpha. Therefore VHL and SDHx mutations both lead to 
induction of genes that would have also been induced via hypoxia and lead to tumor 
development by different mechanisms through the same pathway [11,13]. (Figure 1) A 
mutation in the prolyl hydroxylase domain 2 gene has recently been implicated in a case 
of recurrent paragangliomas and erythrocytosis. This mutation affects PHD2 function and 
stabilizes HIF-α proteins. Also loss of heterozygosity could be indicative that the PHD2 
could be a tumor-suppressor gene [14]. 
Patient with the von-Hippel Lindau disease, an autosomal dominant familial cancer, are 
prone to develop several types of tumors, including renal cell carcinoma and 
pheochromocytoma. Tumors of vascular origin are frequently a common clinical 
presentation in these patients. The VHL gene, located on the chromosome sub-band 
3p25-26, encodes for the VHL protein, whose best characterized function is the 
ubiquitination and consequent degradation via the proteasome of the hypoxia inducible 
factor alpha (HIF-alpha) protein [15]. In patients with VHL disease, the loss of pVHL 
14	
	
function lead to lack of HIF-alpha ubiquitination and degradation and consequent 
upregulation of several hypoxia inducible genes. 
The presence or absence of pheochromocytoma is one of the criteria to classify the VHL 
disease as a type 1 (absence) or type 2 (presence), with the subtype 2C classification 
reserved for families with pheochromocytoma only. Most of the VHL-related 
pheochromocytomas have a loss of the wild type allele as a second hit, according to the 
Knudson’s two hit hypothesis of tumor suppressor genes. 
Pheochromocytomas developing in VHL syndrome have several differences compared to 
the sporadic tumor, including the multifocal location and the earlier onset; more over they 
tend to have a noradrenergic phenotype [16]. 
 
More recently, pheochromocytoma susceptibility has been associated with mutations in 
the succinate dehydrogenase (SDH) gene. Succinate Dehydrogenase is both part of the 
Electron Transport Chain (ETC, complex II) and the Kreb’s cycle, and its sub-units are 
encoded in the nucleus and imported to the mitochondria [17]. THE SDH gene encodes 
for four subunits: SDHA, SDHB, SDHC and SDHD. SDHA (flavinated by the SDHAF2 
protein in the complex) and SDHB (iron-sulfur protein) hold catalytic function and are 
bound to the inner mitochondrial membrane by the SDHC and SDHD subunits. 
Mutations in these subunits cause the complete loss of enzymatic activity in the complex 
and lead to oncogenesis by upregulation of pro-angiogenic response genes [17]. In 
particular mutation in the SDHB subunit has been associated with a high likelihood of 
malignancy [18]. Interestingly, electron channeling through this complex does not result 
in H+ gradient build up and its function is believed to primarily reduce the amount of 
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reactive oxygen species (ROS) that normally leaks from aerobic respiration. 
Pheochromocytomas represent excellent examples of the link between mitochondrial 
function and oncogenic proteins in the promotion of cancer development and the 
metabolic adaptation of tumor cells, combining increased glycolysis with a defective 
mitochondrial respiration. 
The first association made between SDH and tumorigenesis was established by Baysal et 
al [19] when they investigated a hereditary paraganglioma. They were able to map a gene 
designated as PGL1 in the chromosome band 11q23 and later confirmed to code for the 
subunit D of the SDH complex. Shortly after, mutations in genes that codes for sub-units 
B (PGL4) and C (PGL3) were identified as genes of susceptibility [20,21]. Missense, 
frameshift and nonsense mutations predisposing to pheochromocytoma have been 
identified in all the subunits of the SDH complex, including more recently in the SDHA 
subunit [22] and in the SDH5/SDHAF2 gene, identified in patients with head and neck 
paragangliomas [23].  
Dopamine and norepinephrine or dopamine alone characterizes the biochemical 
phenotype in these patients [24]. 
 
1.3.2 The RET and NF1 cluster 
This gene expression cluster is linked together by the activation of kinase signaling 
pathways driven by oncogenes. Activation of receptor tyrosine kinases (RTK) leads to 
downstream activation of several intracellular pathways through a series of consequent 
phosphorylation events. RET and NF1 mutations lead to activation of the 
RAS/RAF/MAPK and the PI3K/AKT/mTOR signaling pathways. TMEM127 mutant 
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tumors clusters with the RET/NF1 group and they enhance mTOR activity independent 
of the above two kinase pathways.  
Microarray expression analysis of KIF1Bbeta mutant tumors also groups with RET/NF1 
tumors though its potential role in kinase pathways is not yet known [11]. 
While the recently discovered MAX gene mutation, which leads to dysregulation of the 
MYC-MAX-MXD1 network, is grouped with this cluster for its connection with mTOR 
pathway [25]. 
The study of families with MEN2 A and B, which develop pheochromocytomas among 
other tumors, allowed the discovery of mutations in the RET (Rearranged during 
Transfection) protooncogene.  The protooncogene RET is a tyrosine kinase receptor 
primarily expressed in neural crest cells (including parasympathetic and sympathetic 
ganglion cells) and urogenital cells [26]. The RET gene was originally found as a novel 
gene rearrangement within the NIH-3T3 fibroblast cell line following transfection with 
DNA from human lymphomas [27]. The name was subsequently used to designate the 
receptor tyrosine kinase within the fused oncogene. The RET gene resides in the 
pericentromeric region of the chromososome 10q11.2 and comprises 21 exons. [27,28]. 
The Ret protein is a transmembrane receptor with an extracellular ligand-binding portion 
containing four cadherin like repeats, a cysteine rich domain and a calcium-binding site. 
Interestingly, such organization makes RET a remote member of the cadherin cell 
adhesion protein superfamily [29]. These phospho-tyrosine residues are important 
docking sites for several intracellular adaptor proteins, making the RET receptor a 
versatile platform for signal transduction. Downstream targets include STAT3, Grb2, 
Grb7 and Grb10, Shc, PLC-gamma and Src, among others, allowing the activation of 
17	
	
major intracellular pathways, including the PI3K/AKT/mTOR, Ras/ERK and JNK 
pathways. Of note, Src is important for Ret signaling through focal adhesion kinase 
(FAK), which is an essential mediator of tumor cell migration and metastasis [30]. 
Gain-of-function point mutations in RET, causing ligand-independent activation of the 
gene product, is the initial oncogenic event in the hereditary cancer syndrome multiple 
endocrine neoplasia type 2 (MEN 2), which recognize three subtypes based on clinical 
presentation: 1) MEN 2A; 2) MEN 2B; and 3) familial medullary thyroid carcinoma 
(FMTC).  Trisomy 10 with duplication of the mutant RET allele, loss of wild-type RET 
allele and tandem duplication with amplification of the mutant RET, are among the 
“second hit” mechanisms identified that favor tumor development in these patients [31]. 
Pheochromocytoma develops in about 50% of patients with MEN 2A and MEN 2B. 
There is a strong correlation between the position of the RET mutation and the clinical 
phenotype. For example, in MEN 2A pheochromocytomas occur more frequently in 
patients with RET mutations in codon 634 and less frequently when the mutation 
involves codons 618, 620 or 791 [32].  
Loss-of-function mutations in the RET gene are responsible for a different congenital 
disorder, known as Hirschprung’s disease (or aganglionic megacolon) in which normal 
enteric nerves are absent[33]. The occurrence of this disease reinforces the importance of 
RET in directing cells of the neural cell crest (which later become ganglionic cells) 
during development, and, as an important disease-causing gene. 
 
Several groups have suggested that mutant RET in MEN 2B activates additional aberrant 
signaling pathways, which account for the more aggressive phenotype in patients with 
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this syndrome compared to patients affected by MEN 2A. Interestingly, also RET 
mutations in MEN 2A occur mainly in the extracellular domain cysteine residue, causing 
alterations in receptor dimerization, while MEN 2B RET mutation are predominantly 
located in the intracellular domain, resulting in activation of different signaling pathways 
and consequent expression of different target genes. Expression microarray analysis 
supports these conclusions [34]. Patients with MEN 2 syndrome have 
pheochromocytomas that secrete predominantly epinephrine [24]. 
The tumor suppressor gene Neurofibromatosis type 1 (NF 1) encodes for the protein 
neurofibromin, a GTPase-activating protein in the RAS signaling cascade and mTOR 
signaling pathway [35]. In patients with mutation in this gene, in conjunction with other 
tumors, pheochromocytoma is present in up to 5% of cases and it is frequently diagnosed 
later in life [36]. Neurofibromatosis is diagnosed clinically by a thorough physical 
examination or a positive family history so confirmation of diagnosis does not require 
genetic testing. Neurofibromatosis patients with pheochromocytomas produce both 
epinephrine and norepinephrine [24]. 
Studies on transgenic mice with NF1 mutations have clearly linked this gene with the 
development of pheochromocytoma. In addition, the only available mouse 
pheochromocytoma cells lines (the MPC cells and its derivative MTT cells) that we are 
using for pre-clinical experimentation were derived from this mouse model [37,38]. 
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1.3.3 Other genes 
Next generation sequencing technology and improvement in our understanding of the 
molecular basis of the disease, have allowed the discovery of newer pheochromocytoma 
susceptibility genes. 
Screening more than one hundred samples from a large institutional collection of 
pheochromocytomas and paragangliomas, several germline mutation were identified in 
the TMEM127 gene [7], which encode for a transmembrane protein; although the 
function of TMEM 127 protein is not well characterized, a link with the mTOR pathway 
has been identified. Indeed, TMEM127 is involved in endosomal organelle dynamics, 
which may contribute to its modulation of mTOR kinase signaling [6]. Interestingly, 
tumor samples from patient with TMEM127 mutations have an increased activation of 
mTORC1[39]. Patients with TMEM127 mutation tend to have benign, bilateral adrenal 
pheochromocytomas; a clear association with other tumors still needs to be clarified.  
 
Using exome sequencing, Comino-Mendez et al. [40] were able to identify MAX gene 
mutations in three independent familial cases of pheochromocytoma; the inactivating 
nature of the germline mutation points to a tumor suppression function for this gene. As 
mentioned before, the MAX (MYC-associated factor X) protein is a key component of 
the MYC-MAX-MXD1 cellular network, involved in several functions, including 
proliferation, differentiation and apoptosis. These tumors tend to be bilateral and are 
associated in 25% of cases with malignant behavior [41].  
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In summary, classification of pheochromocytoma into two clusters we described above is 
widely accepted to distinguish tumorigenesis amongst the multiple mutations observed. 
However, there is another proposed theory that different susceptibility genes converge 
into a single common pathway of tumorigenesis. According to this model the germline 
mutations in RET, VHL, NF1 and SDHx prevent apoptosis of the neuronal progenitor 
cells. Normally during embryogenesis as nerve growth factor becomes limiting, c-Jun 
becomes activated and induces the neuronal progenitor cells to undergo apoptosis [11]. 
The recognition that germline mutations in the genes described above are important in the 
pathogenesis and clinical presentation of patients with pheochromocytoma, provide a 
solid justification for genetic testing as an important part of patient management. 
As new genes are identified as susceptibility genes for pheochromocytoma, this is going 
to be true even more so in the future. Clinical presentation, family history and 
histopathological and radiological characteristic of the tumor help guide the sequence in 
which genes must be tested.  
 
1.4 Diagnosis 
It can be difficult to decide which patients should be subjected to a work up for suspected 
pheochromocytoma, because is a rare disorder with a frequently aspecific clinical 
presentation [1].  A newer test measuring the urinary and plasma metanephrines has 
substituted the previously used urinary or plasma catecholamines measured to screen for 
pheochromocytomas. This is a better test because these metabolites of the catecholamines 
are released continuously from the tumor independent of the time of catecholamine 
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release. Thus plasma free metanephrines would offer better diagnostic sensitivity over 
other tests [42].  
Increases in the plasma concentrations of normetanephrine and metanephrine four times 
above the upper reference limit are almost non-existing in patients without 
pheochromocytoma but occur in 70-80% of patients with the tumor [43]. In a recent 
study Eisenhofer et al concluded that plasma methoxytyramine (>0.2 nmol/L) is a novel 
biomarker for metastatic pheochromocytomas and paragangliomas. Such patients have 
increased likelihood of SDHB positivity, tumor size (>5 cm) and extraadrenal location of 
their tumor all predictors for higher likelihood of malignancy [44]. 
In patients with levels in the intermediate range that is above normal and below four 
times normal a clonidine suppression test is done to confirm the diagnosis.  
Chromogranin A is an acidic protein that is stored with catecholamines in secretory 
granules and co released with them. It is not specific for pheochromocytomas but 
elevated levels are seen with many neuroendocrine tumors. Chromogranin A has a 
sensitivity of 83-89% for identifying pheochromocytomas and maybe elevated in both 
non-secretory and secretory tumors. High plasma levels indicate malignancy and 
correlate with tumor mass. Their levels may also be used to gauge tumor response and 
relapse [45]. 
 
Once the diagnosis of pheochromocytoma/paraganglioma is made with a positive 
biochemistry it is necessary to locate the tumor for surgical resection. Anatomical 
imaging is most widely used in the initial evaluation of patients as it is offers the 
advantages of low cost, almost universal availability, and less skill for use [5]. CT scan 
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can be used to localize adrenal tumors > 1 cm and extra adrenal tumors > 2 cm [46]. MRI 
with or without gadolinium enhancement is superior for the detection of extra-adrenal 
tumors. [47] Inspite of their excellent sensitivity, CT and MRI lack the specificity 
required to confirm a mass as a pheochromocytoma and thus functional imaging 
modalities are used which have a higher specificity for detection [5]. 
Whole body scanning using MIBG labeled with radioiodine (MIBG scintigraphy) has a 
higher specificity and helps to overcome the limitations of anatomical imaging [48]. 
MIBG scanning may be carried out with either 123I or 131I. MIBG scanning with 123I 
offers a number of advantages over 131I like much better sensitivity [49,50], additional 
utility for imaging by SPECT and shorter half-life hence higher doses can be used [50]. A 
recent study however found that low-dose diagnostic 123I-MIBG whole-body scans at 6h 
and 24h detect less lesions compared to 3 days post treatment 131I-MIBG whole-body 
scan in malignant pheochromocytoma and paraganglioma [51]. Positron Emission 
Tomography is another functional modality used due to its superior spatial resolution and 
low radiation exposure. 18F-DA PET is more sensitive overall than 123I-MIBG 
scintigraphy or somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide on a per 
patient basis. Hence it should be used in the evaluation of pheochromocytomas if 
available and if unavailable 123I-MIBG scintigraphy should be used for nonmetastatic or 
adrenal pheochromocytomas and SRS should be used for metastatic pheochromocytomas 
[52]. Since pheochromocytomas and paragangliomas at different sites take up these 
biomarkers for imaging differently the sensitivity of various functional imaging studies 
varies for tumors according to site. Adrenal tumors should be imaged with either 123I-
MIBG scintigraphy, 18F-DA PET or 18F-DOPA PET to detect/exclude multifocal or 
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metastatic disease. Adrenal tumors associated with a VHL gene mutation are best imaged 
by 18F-DA PET. In patients with extra-adrenal tumors imaging with MIBG is often not 
very accurate and imaging with 18F-DA PET or 18F-DOPA PET is a better approach. 18F-
DOPA PET is particularly useful to detect head and neck paragangliomas. In patients 
with metastatic pheochromocytomas and paragangliomas 123I-MIBG scintigraphy has a 
limited role unless it is being used to determine whether or not the patient is eligible for 
131I-MIBG treatment. It is found that 18FDG PET is superior in patients with metastatic 
SDHB paragangliomas and the 18F-DOPA PET performs poorly. This 
radiopharmaceutical FDG is non-specific and taken up by rapidly growing tumors hence 
it can be used in patients with metastatic pheochromocytoma that is becoming 
undifferentiated to take up more specific agents. Provided that somatostatin receptors are 
not lost during dedifferentiation somatostatin analogues like 111In-penetreotide, 68Ga-
DOTATOC and 68Ga-DOTANOC maybe useful [5,53,54]. 
 
  Genetic testing is important in patients who are <45 years, with multiple tumors, 
extra-adrenal tumors, family history, metastatic tumors and increased dopamine 
secretion. Decision for the sequence in which to test the genes is based on clinical 
presentation and investigations. About 40-50% patients with malignant 
pheochromocytoma will have mutations in SDHB (35%), VHL (5%) and SDHD 
(1%) and hence should be offered testing for at least these 3 genes. The importance of 
genetic testing lies in that it helps predict prognosis for the patient, risk for the family and 
helps guide therapy [41].                                                                                                                                      
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In individuals who meet the criteria for genetic testing but for whom clinical 
indicators, biochemical indicators and imaging do not indicate which genes to test 
immunohistochemistry seems to offer an opportunity to narrow the mutations that should 
be tested for. 
In an individual with SDHB positive immunohistochemistry staining one should test for 
VHL, RET or NF1 mutations. In those with negative staining implying absence of SDHB 
protein expression one should test for SDHB, SDHC or SDHD mutations. SDHB 
immunohistochemistry has a sensitivity of about 100% and a specificity of about 84% in 
a prospective series to detect the presence of an SDH mutation [55,56]. SDHA 
immmunohistochemistry has recently been shown to reveal the presence of SDHA 
mutations in about 3% of patients who are affected by apparently sporadic tumors [57]. 
 
There are no histological features that are certain for malignancy and the presence 
of lymph node involvement or distant metastases is the only widely accepted criteria for 
malignancy. About 10% of pheochromocytomas are malignant at the time of initial 
surgery or at follow up. The clinical value of the Pheochromocytoma of the Adrenal 
Gland Scaled Score (PASS score) based on invasion, diffuse growth, focal or confluent 
necrosis, high cellularity or tumor spindling has not been confirmed. Tumors that have 
increased likelihood of malignancy are usually larger in size, extra-adrenal, and secrete 
more dopamine. Also an index of tumor differentiation the epinephrine to epinephrine 
plus norepinephrine ratio, is lower in malignant than benign tumors [58,59]. 
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1.5 Traditional therapeutic options 
A  multi-disciplinary, patient-centered approach is frequently required for an adequate 
management of patients with pheochromocytoma. This is accomplished byinvolving a 
number of specialists including an endocrinologist, a surgeon, an anesthesiologist and an 
oncologist at the very least along with ancillary staff.  
The ultimate goal of therapy is tumor removal. In benign tumors this is more easily 
accomplished and once the tumor is removed the patient can have a normal symptom free 
life. However at the time of diagnosis it may be difficult to accurately distinguish patients 
who have benign tumors from patients with malignant tumors, so all patients need follow 
up to detect recurrence or malignancy. 
Blood pressure control pre and intra-operatively to avert a hypertensive crisis is the 
cardinal medical management task. Postoperative hypotension maybe a risk and hence 
the patients need to be monitored closely as well. Most patients with  hypertension are 
adequately controlled using the  irreversible non-competitive alpha-blocker 
phenoxybenzamine. A portion of  patients with clinical symptoms of beta-receptor 
stimulation (palpitations, anxiety, and chest pain) may need a beta-blockade (propranolol, 
atenolol or metoprolol). A beta-blocking agent should never be used in absence of an 
alpha-blocking agent as that could precipitate a hypertensive crisis [60]. Metyrosine a 
competitive inhibitor of tyrosine hydroxylase, the rate-limiting step in catecholamine 
synthesis decreases production of catecholamines thus making pre and intra operative 
blood pressure control easier [61].  
Laparoscopic adrenalectomy is a safe and effective approach in most patients with a 
benign pheochromocytoma less than 6 cm and offers significant post-operative benefits. 
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Patients with large adrenal tumors (larger than 6 cm), evidence of venous involvement, or 
invasion into surrounding tissue should be approached cautiously [62,63]. Posterior 
retroperitoneoscopic adrenalectomy is now becoming the preferred approach for patients 
with PHEO [64]. It is a technique that is safely performed for a variety of adrenal lesions 
and is ideal for patients who have undergone earlier abdominal surgery, and is feasible in 
obese patients [65]. Patients with hereditary adrenal pheochromocytomas may undergo 
adrenal cortical sparing surgery, which is an alternative approach that aims to balance 
tumor removal with preservation of adrenocortical function [66]. The plasma or urinary 
metanephrine concentration should be checked 10 days after surgery, as catecholamine 
levels may remain high for the first week after tumor resection until all the extratumoral 
pools of catecholamines have emptied [58]. In malignant disease, surgical debulking of 
the recurrence or metastases is the primary management. In patients not amenable to 
surgery or in those that require additional therapy post surgery a number of palliative 
options are available, as discussed below.   
131I-MIBG therapy is indicated in patients with malignant inoperable 123I-MIBG positive 
pheochromocytomas or paragangliomas. Its contraindications are mainly related to 
radiation safety and toxicity. Thyroid blockade with potassium iodide is necessary to 
protect the gland from radiation. The main side effects of this therapy are vomiting and 
rise in blood pressure (early side effects) and myelotoxicity and hypothyroidism inspite 
of blockage (late side effects). The routine initial dose in treatment of 
pheochromocytomas and paragangliomas is about 15-18.5 GBq (405-500 mCi). Doses 
greater than that show a significant increase in hematological toxicity without an 
additional improvement in response rate [67]. 
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In rapidly progressing metastatic pheochromocytomas, the use of chemotherapy is the 
preferred treatment option. A combination of cyclophosphamide, vincristine and 
dacarbazine (CVD) have shown a 57% complete or partial radiologic response while 79% 
had some biochemical response [68]. The NIH updated this study with 4 more patients 
(total 18 patients) and followed them for 22 years. 55% patients had radiologic response 
to treatment and 72% had a biochemical response. This imply that CVD therapy is not 
indicated in every patient with metastatic disease, and should be used for patients with 
symptoms where tumor shrinkage might be beneficial and could lead to possible surgical 
resection. Based upon long-term follow-up, there is no statistically significant difference 
in overall survival between patients whose tumors responded to CVD compared to those 
whose tumors did not respond [69]. In another study done in 2011, around 33% of 
patients with metastatic pheochromocytoma/sympathetic paraganglioma experienced 
improvements in tumor size or hypertension (dose reduction/antihypertensive 
discontinuation) after chemotherapy. They also observed a trend toward longer survival 
in the responders than in the nonresponders to chemotherapy. Cyclophosphamide and 
dacarbazine combined with vincristine-based and/or doxorubicin-based chemotherapy 
was the regimen received by these patients [70]. CVD therapy can cause a hypertensive 
crisis due to catecholamine release during treatment and hence patients should be blocked 
beforehand [71]. 
Radiation therapy does not prevent local recurrence and cannot be used as a primary 
mode of therapy. This therapeutic option is mainly beneficial for relief from symptoms 
and pain associated with bone and lymph node metastasis [71]. Less commonly used 
option includes radiofrequency (RF) ablation (to control disease locally and alleviate 
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symptoms like pain and hypertension related to the tumor). Bone, chest wall, and 
retroperitoneal lesions are treated with either RF ablation or cryoablation, and liver 
tumors are treated with either RF ablation or ethanol ablation [72]. 
When recurrences are small with an accessible vascular supply surgical removal maybe 
preceded or replaced with therapeutic embolization. Preoperative embolization of the 
tumor can minimize blood loss and facilitate subsequent resection. Transcatheter arterial 
chemo-embolization (TACE) is particularly useful in hepatic metastases and can lead to 
significant reduction of the tumor mass (number and size of the lesions) in the liver 
without any major side effects. An increase in blood pressure after every TACE could be 
controlled by sufficient preadministration of an alpha-blocker [73]. Different approaches 
and embolizing agents has been described in the literature [74,75]. 
 
Another therapeutic approach is represented by Peptide Receptor Radionuclide Therapy. 
The somatostatin receptors are expressed in pheochromocytomas, particularly subtype 2A 
and 3 [76]. This therapy utilizes radiolabelled 111In, 90Y, or 177Lu-labelled somatostatin 
analogues and is of use in patients with unresectable metastatic disease. Symptomatic 
improvement may occur with all radiolabelled somatostatin analogues though tumor size 
reduction is achieved with 90Y and 177Lu. High tumor uptake on somatostatin receptor 
scintigraphy and limited amount of liver metastases predict higher likelihood of tumor 
remission. Serious side-effects like myelodysplastic syndrome or renal failure are rare. 
The median duration of the therapy response for [90Y-DOTA(0),Tyr(3)]octreotide is 30 
months and for [177Lu-DOTA(0),Tyr(3)]octreotate it is more than 36 months. This 
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treatment is being used for neuroendocrine tumors and is now gaining popularity for 
pheochromocytomas as well [77]. 
 
Overall, the long-term survival of patients after successful removal of a benign 
pheochromocytoma is basically the same as normal individuals adjusted for age due to 
advances in surgery and a multi-disciplinary approach in the management of these 
patients [78]. Patients should be followed up lifelong with annual check-ups of blood 
pressure measurement and urine or plasma metanephrine levels [58]. 
 
1.6 Emerging therapies 
Especially for patients with malignant tumors. the therapeutic regimens above 
described have only limited efficacy and a great potential of significant toxicity and 
recurrence. Many of these treatments were introduced into clinical practice before the 
discovery of the genes and the molecular pathways responsible for onset of these tumors 
and exhibits nonselective cell toxicity. 
A group of novel treatment agents, the so-called “targeted molecular therapies”, are 
emerging as a promising therapeutic option for several cancers [79]. At the moment, this 
promising cancer treatment option has been only marginally evaluated in 
pheochromocytoma. For example, the knowledge that chromaffin cell in tumors, 
especially the malignant forms, express high levels of vascular endothelial growth factor 
(VEGF) and other angiogenic factors, has prompted the use of inhibitor directed against 
these proteins and related pathways as a new treatment modality [80]. Sunitinib is a 
potent tyrosine kinase inhibitors targeting VEGF, platelet derived growth factor (PDGF), 
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RET, c-Kit and the FLT-3 receptors. Sunitinib has demonstrated promising results in a 
patient with advanced pheochromocytoma occurring within a VHL-syndrome [81], 
achieving radiologic partial remission and improved performance status after 6 months of 
therapy. In another study, thalidomide, which reduces VEGF levels, in combination with 
temozolomide, was tested in another patient with pheochromocytoma with partial 
radiologic response [82]. The limited number of patients involved in these clinical trials 
warrant only a cautious optimism, with the hope to include more patients in future 
studies. Other targeted therapies, including imatinib and everolimus, did not revealed 
positive results in a small subset of patients with pheochromocytoma [83,84]. A number 
of new therapeutic targets are being considered such as mTOR inhibitors, HIF inhibitors, 
Prolyl hydroxylase activators ERBB2 inhibitors and heat shock protein 90 inhibitors [71]. 
Altogether, these trials reveal that further studies are needed to evaluate this new class 
of medications as a possible treatment for malignant pheochromocytomas and 
paragangliomas. 
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2. MATERIAL AND METHODS 
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2.1  Cell line and reagents 
The mouse pheochromocytoma cell lines MPC [85] and the metastatic MPC-derived 
MTT cell line [38] were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 5% horse serum (Gibco, Invitrogen), 
and antibiotic/antimycotic.  The highly metastatic MTT cells were generated by 
disaggregation and culture of tumor cells from a liver metastasis resected from mice 
inoculated with MPC cells, as described previously [38].  MTT-luc cells were generated 
by retroviral transduction of MTT cells with the firefly luciferase gene, as described 
previously [86]. The rat pheochromocytoma cell line PC12 [87] was maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and antibiotic/antimycotic.  The mouse and rat pheochromocytoma cell 
lines were grown until 80% confluence, detached using 0.05% trypsin/EDTA, and 
resuspended in phosphate-buffered saline (PBS) at 5 x 105 cells/200 l for injection.   
D-luciferin potassium salt (Caliper LifeSciences) was diluted in PBS at a concentration of 
15mg/ml, filter-sterilized in a 0.22um filter, aliquot and stored and -20 C until use. 
 
AZD8055 was provided by Astra-Zeneca (London, UK). Torin-1 was developed by the 
Dana-Farber Cancer Institute, Biological Chemistry and Molecular Pharmacology 
section, Harvard Medical School (Boston, MA). All of the compounds were dissolved in 
DMSO; stock solutions were stored at -20C and thawed prior to use. Controls were 
treated with the highest concentration of DMSO in the panel. 
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The Hsp90 inhibitor 17-AAG was provided by the Cancer Therapy Evaluation Program 
at NCI-Frederick (Frederick, MD). The new generation Hsp90 inhibitor STA-9090 
(Genatespib) was provided by Synta Pharmaceutical Corp. (Lexington, MA). 
 
2.2  pLLuc construct and retroviral transduction 
 The EGFP gene in the retroviral vector pLEGFP-N1 (Clontech) was replaced with the 
firefly luciferase gene generated via PCR from the pGL3-Basic (Promega) vector and 
inserted between the BamH-1 and Not-1 sites resulting in the pLLuc retroviral vector. 
The retrovirus packaging cell line Amphopak-293 (Clontech) was transfected with the 
pLLuc retroviral vector to generage 293pLLuc cells. Selection with G418 enabled the 
generation of stably transfected 293pLLuc cells. Target cells were transduced with pLLuc 
by incubating them overnight with conditioned medium obtained from 293 pLLuc cells 
containing retroviral particles and filtered through a 0.45 mm filter to remove any cellular 
debris. Transduced cells were incubated with the filtered supernatant overnight and 
selected with G418 to generate stable cell lines expressing luciferase. 
 
2.3  Animal experiment and BLI imaging 
All animal studies were conducted in accordance to the principles and procedures 
outlined in the National Institutes of Health (NIH) Guide for the Care and Use of 
Animals and approved by the NIH Animal Care and Use Committee (ACUC).   
Cells were growth until 80% confluence, then cells were detached using 0.05% 
Trypsin/EDTA, incubated for 3 minutes at 37 C and resuspended and counted to obtain 
the desired concentration. For the experiments involving the development of the animal 
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models, we obtained a concentration of 0.5 x 10^6 cell/200 l before injection. Cells 
were injected tail vein or subcutaneously into female athymic nude mice (Taconic, 
Germantown, MD). Experimental groups consisted of 10 weeks old mice (n=6 for the 
experimental animal model experiments and for the spontaneous metastasis model) 
housed in a pathogen-free facility. The animals were imaged weekly by both 
Bioluminescence (BLI) and/or MRI imaging (described below). For BLI imaging, mice 
were anesthetized with isofluorane, injected with 0.1 mg/gr D-luciferin and imaged after 
15 minutes as described below (MRI imaging) and then euthanized using CO2 inhalation 
and cervical dislocation. Several organs from the mice were dissected and preserved in 
10% formalin. 
For the experiment involving the use of the mTORC1/2 inhibitors (using the spontaneous 
metastasis model) 1.5 x 10^6 MTT-luc cells were injected subcutaneously in the right 
flank of female athymic nude mice (Taconic, Germantown, MD). The experimental 
group in this set of experiments consisted of 10 weeks old mice (n=7) housed in a 
pathogen-free facility. After 10 days, allowing for tumor cells to engraft, we started a 
treatment with 20 mg/kg of AZD8055 in one group of animals (n=7). Animals in control 
group (n=7) were treated with the same volume of vehicle instead, on a daily, seven days 
out of seven schedule. The animals were imaged weekly by Bioluminescence (BLI, 
described below).  
For the experimets involving the testing of Hsp90 inhibitors: for the experimental 
metastasis model 0.5 x 105 MTT-luc cells were injected into the tail vein of female 
athymic mice (Taconic Farms).  For the spontaneous metastasis model 1.5 x 106 MTT-luc 
cells were injected subcutaneously in the right flank of female athymic mice.  
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Experimental groups consisted of mice injected at 10 weeks (n=6 for 17-AAG; n=8 for 
ganetespib), housed in a pathogen-free facility.  The animals were imaged weekly by 
bioluminescence imaging (BLI) as described below.  For BLI imaging, mice were 
anesthetized with isoflurane, injected with 150mg/kg D-luciferin and imaged after 15 
minutes as described below.  For the experimental metastasis model (MTT-luc cell tail 
vein injection) we performed survival experiments; the endpoint criteria for euthanasia 
(performed by CO2 inhalation and cervical dislocation) included a significantly hunched 
posture, significantly rough fur, a body condition score (BCS) of 1 (a BCS of 3 is ideal, 
with 2 representing a thin condition and 1 when the animal is emaciated), or a pain score 
(PS) of  > 3 (a PS of 1 indicates no pain or distress; 2 indicates mild or transient pain or 
distress; and 3 and 4 indicate moderate to severe pain/distress, respectively). Conditions 
of the animals, including pain levels, were monitored daily. For the spontaneous 
metastasis model, on day 49, after in vivo bioluminescence measurements were taken, the 
animals were euthanized (using CO2 inhalation and cervical dislocation), and both lungs 
and liver were excised and luciferase activity quantified.  The organs from the mice were 
dissected and preserved in 10% formalin. 
 
2.4 Hsp70 secretion 
Secreted Hsp70 was measured in mouse plasma by enzyme-linked immunosorbent assay 
(ELISA; Assay Designs Inc.), following the manufacturer’s protocol.  Briefly, blood of 
tumor-bearing mice was collected before and 6 hours after intraperitoneal (i.p.) injection 
of 17-AAG as indicated.  Plasma was separated by centrifugation (4°C, 14000 rpm, 10 
minutes) and kept at -80°C until analysis.  
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2.5 Bioluminescence Imaging 
All bioluminescent data were collected and analyzed with a Xenogen IVIS system (IVIS; 
Calipers, Perkin Elmer).  
In vitro imaging, MTT-luc bioluminescent cells were serially diluted from 4000 to 8 cell 
in DMEM media in a 96 well plate, and D-luciferin at a concentration of 150 ug/ml was 
added directly to the media 10 minutes before imaging. Imaging was performed at 20 
seconds/plate. 
For in vivo imaging, luciferase activity was performed on anesthetized animals (1-2% 
isoflurane) 15 min following i.p. administration of 150mg/kg luciferin in phosphate-
buffered saline. The mice were then placed inside a light-tight box under continous 
exposure to 1-2% isofluorane. The experiments were performed in the NIH Mouse Image 
Facility in accordance to ACUC regulations. 
All imaging variables were equals and photographic and bioluminescent images at 
different time point were collected for each sample. The bioluminescence data are 
presented visually as a color overlay on the photographic image. Using the Living Image 
software (Caliper, Perkin Elmer),  a region of interest (ROI) was drawn around tumor 
sites of interest and the total photons count or photons/s was quantified. 
 
2.6  MRI 
For MRI, anesthesia was induced in a chamber with 5% isoflurane in an 80%/20% 
medical air/oxygen mixture.  The mouse was then transferred to a cradle with a built in 
mask and anesthesia was maintained at 30-45 breaths per minute with 1-2% isoflurane.  
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Temperature was maintained by blowing heated air through the bore of the scanner. 
(Bair-Hugger/Arizant, Eden Prarie, MN) 
All scans were performed using a 7 Tesla Bruker Biospec system (Bruker-Biospin, 
Billerica, MA) and a 35mm linear bird cage coil.  Each data set consisted of an initial 
locator scan, followed by a T2-weighted scan, and a proton density weighted scan.  To 
reduce motion artifacts, the acquisition was gated so that acquisition occurred between 
breaths (Small Animal Instruments, Inc. Stony Brook, NY).   
T2-weighted images consisted of twelve 1mm slices over a 6x3cm FOV acquired using a 
RARE (Rapid Acquisition Relaxation Enhanced) sequence.  The image matrix was 
256x256 and 4 echoes were acquired per excitation.  The effective echo time was 20.6ms. 
Proton density weighted images consisted of twelve 1.5mm slices over a 3x3cm FOV 
acquired using a FLASH (Fast Low Angle Snapshot) sequence. The image matrix was 
256x256, TE was 3ms, and the excitation flip angle was 30 degrees. 
 
2.7 Real-time PCR 
Real-time PCR was performed on a 7500 Real Time PCR System (Applied Biosystems) 
using detector Taqman, reporter FAM and quencher TAMRA for the genes and detector 
VIC for 18S rRNA. Primer sequences TaqMan® Gene Expression Assays were from 
Applied Biosystems as recommended for the genes. Primers were premixed to a 
concentration of 18 M for each primer and 5 M for the probe, which represented a 20X 
mix. Final reaction volume was 25 l; amounts of templates for 18S rRNA and for other 
genes were 5 ng and 25 ng, respectively. PCR reaction was performed as follows:  50°C 
for 2 minutes, 95°C for 10 minutes, and 50 cycles of two-step PCR (95°C for 15 seconds 
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and 60°C for 1 minute).  The results were analyzed by 7500 system software, version 1.3 
(Applied Biosystems), calculated based on the delta-delta Ct method and then by 
Microsoft Excel. Each result was correlated to the housekeeping gene 18S rRNA.  
 
2.8 Drug treatment and western blotting 
MTT cells in logarithmic growth (~70% confluent) were treated with the indicated 
concentrations of rapamycin, AZD8055 or Torin-1 for 6 hours, or  
17-AAG or ganetespib for 20 hours at 37oC in 5% CO2.  Control cells were incubated 
with the vehicle for the same period of time. Cells were washed twice  with cold PBS and 
lysed in TNESV lysis buffer (50 mM Tris-HCl pH 7.5, 2 mM EDTA, 100 mM NaCl, 1 
mM sodium orthovanadate, 1% Nonidet P-40) or Cell lysis buffer (Cell Signaling) 
supplemented with CompleteTM (Roche) protease inhibitors cocktail).  Protein lysates 
were denatured by boiling in 4X sodium dodecyl sulfate (SDS)-sample buffer for 5 
minutes.  Nuclear extracts were prepared as described by Isaacs et al. [88].  Proteins were 
separated by 4-20% gradient SDS-PAGE (Bio-Rad Laboratories) and transferred to a 
polyvinylidene fluoride (PVDF) membrane (Millipore).  
For the experiment involving the use of the mTORC1/2 inhibitors, the membranes waere 
incubated with total-Akt, phospho-Akt (Ser473), phospho-S6 (Ser235/236), phospho-S6 
(Ser240/244), phospho-eEF2k (Ser366), phospho-eIF4B (Ser422), and actin primary 
antibodies (Cell Signaling) overnight at 4C which was followed by washing and 
incubation with the HRP- conjugated secondary antibody at RT for 1h. The blots were 
visualized using Amersham ECL Plus Western Blotting Reagents.   
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For the experiment involving the use of the Hsp90 inhibitos, PhosphoS473-Akt  and Akt 
(Cell Signaling Technology), HIF-1α (Santa Cruz Biotechnology) and tubulin (BD 
Pharmingen, for loading control) were measured by immunoblotting.  For poly(ADP-
ribose) polymerase (PARP) cleavage, MTT cells were treated with the indicated 
concentrations of 17-AAG or ganetespib for 20 hours at 37oC and 5% CO2.  PARP (Cell 
Signaling Technology) and actin (Millipore, for loading control) were measured by 
immunoblotting. 
For the experiment involving the use of drugs from the NPC library: for PARP cleavage, 
MTT cells were treated with the indicated dose and concentration of drug for 20 hrs at 
37ºC and 5% CO2. Cleaved and full-length PARP (rabbit anti-PARP antibody from Cell 
Signaling and HRP-conjugated anti-rabbit antibody from Jackson ImmunoResearch) and 
actin (mouse anti-actin antibody from Millipore and HRP-conjugated anti-mouse 
antibody from Jackson ImmunoResearch), for loading control, were measured by 
immunoblotting. 
 
2.9 Cell proliferation assay 
Cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay.  MTT cells (15 × 103) were incubated in 96-well 
plates for 24 hours in complete medium before the addition of the indicated 
concentrations of rapamycin, AZD8055,  Torin1 or 17-AAG and ganetespib.  A solution 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (1 mg/ml; Sigma-
Aldrich) was added and plates were incubated at 37°C for 3 hours before measuring 
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absorbance at 562 nm using a Wallac Victor 3 1420 Multilabel plate reader (Perkin 
Elmer). 
 
2.10 Cell migration assay  
Cell migration was measured using modified Boyden chambers / Transwell assay (BD 
Biosciences).  MTT cells were seeded at 150,000 cells per chamber, and cell migration 
was stimulated for 24 hours with serum (10%) in the absence (control) or presence of the 
drugs (AZD8055 and Torin1; 17-AAG or ganetespib) using the indicated doses.  After 24 
hours cells were fixed and stained using the Diff-Quick assay (Dade Behring Inc.).  Mean 
values from four fields (1 × 1.4 mm) were calculated for each of triplicate wells per 
condition.  IC50 values were determined using Graph Pad Prism software (Graph Pad 
Software).  Bright field images were digitally acquired using an Olympus 
photomicroscope and IPLab software (Scanalytics). Mean values from four fields (1 × 1.4 
mm) were calculated for each of triplicate wells per condition. IC50 values were 
determined using GraphPad Prism software. 
 
2.11 Ethics Statement 
All animal studies were conducted in accordance with the principles and procedures 
outlined in the National Institutes of Health (NIH) Guide for the Care and Use of 
Animals and were approved by the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Animal Care and Use Committee,(Animal Study 
Proposal #12-028 and the PHS Assurance # A4149-01). Pheochromocytoma tumor tissue 
was obtained from  patients visiting the Clinical Center (Institutional Review Board 
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(IRB) protocol # 00-CH-0093) at the National Institutes of Health (NIH), in accordance 
with the principles and procedures outlined in the NIH IRB Guidelines, and this was 
approved by the Institutional Review Board of Eunice Kennedy Shriver National Institute 
of Child Health and Human Development (NICHD) NIH.  All patients signed an IRB 
approved consent that allowed for the collection of tissue samples  
 
2.12 Human samples 
Pheochromocytoma tumor tissue for the real time PCR and for drug testing was obtained 
from patients visiting our clinic (Institutional Review Board (IRB) protocol # 00-CH-
0093); the study was approved by the IRB of the NICHD/NIH, and patients gave written 
informed consent. Table 1 and table 2 summarize patient clinical information. Guidelines 
for genetic testing was previously described [89]. Normal human adrenal medulla (n=4) 
was obtained form anonymous organ donors with absent adrenal tumor or dysfunction 
and collected within 2-5 hours after confirmed brain death at the Department of Urology, 
School of Medicine, Comenius University, Bratislava, Slovakia. Separation of cortex 
from adrenal medulla was ascertained as previously described [90].  
 
2.13  Histopathology 
In order to confirm the presence of pheochromocytoma tumor cells, we removed from the 
mice selected tissues and preserve them in 10% formalin immediately after ex vivo 
imaging. Tissues were paraffin embedded, sectioned and stained with hematoxylin and 
eosin, and analyzed by microscopy using a Leica microscope. 
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2.14 Tumor dissociation and tyrosine hydroxylase immunocytochemistry in 
primary cell culture 
Pheochromocytoma tumor tissue obtained from two patients visiting our clinic 
(Institutional Review Board (IRB) protocol # 00-CH-0093) was minced to 2-3 mm pieces 
in a 100 mm Petri dish.  The pieces were transferred to 15 ml Falcon tubes filled with 
culture medium containing collagenase B (1mg/ml; Roche Applied Science).  The tissue 
pieces were incubated for 1 hour at 37C, rocking the tube gently every 10 minutes.  The 
pieces were allowed to settle, and the supernatant was aspirated and transferred to a new 
Falcon tube.  The cell solution was centrifuged at 1,000 rpm/minute for 5 minutes.  The 
pellets were resuspended in complete culture medium and the cells were seeded in 96-
well plates coated with collagen IV (BD Biosciences).  The following day, cells were 
washed with PBS and medium was added containing different concentrations of the drug  
( AZD8055 or 3uM Torin-1; ganetespib).  The final concentration of DMSO did not 
exceed 0.03% including control wells.  The cells were treated every other day for 10 
days, with drug washout and readministration every two days. On day 10, the primary 
cultures were washed with PBS, incubated with H2O2 and blocked for 1 hour at room 
temperature.  The cells were then incubated with primary anti-tyrosine hydroxylase (TH) 
antibody (Immunostar), diluted 1:500 in Signal Stain® Ab Diluent (Cell Signaling 
Technology), in humidifying chambers at 4C overnight.  TH is a marker of 
catecholamine-synthesizing ability, in order to discriminate tumor cells from non-
neoplastic fibroblasts and other cell types in primary cultures [91].  The following day, 
cells were incubated with secondary anti-mouse-horseradish peroxidase (HRP)-
conjugated antibody (Dako EnVision+ System- (HRP) Labeled Polymer; Dako) in 
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humidifying chambers at room temperature for 1 hour.  The antigen-antibody interaction 
was visualized using Dako Liquid diaminobenzidine (DAB) + Substrate Chromogen 
System.  The cells were counterstained with Mayer`s hematoxylin solution (Sigma-
Aldrich) for 5 minutes and washed in dH2O. Glycerol was added to prevent cells from 
drying and imaged immediately.  TH-positive cells were counted and normalized to 
control (untreated) cultures. 
 
2.15 Quantitative high-throughput proliferation assay summary and protocols for 
MTT cells 
Cell viability after compound treatment was measured using a luciferase-coupled ATP 
quantitation assay (CellTiter-Glo, Promega) in MTT cells. The change of intracellular 
ATP content indicates the number of metabolically competent cells after compound 
treatment. MTT cells were harvested from T225 flasks and resuspended in DMEM 
medium with 5% FBS and 1% horse serum. Then 5µl of a suspension of 200,000 cells/ml 
was dispensed into each well of white, solid bottom, 1536-well tissue culture–treated 
plates using a Multidrop Combi dispenser. After overnight culture at 37°C with 5% CO2, 
a total of 23 nl of compounds at 8 selected concentrations from the NPC or positive 
control (10mM stock of doxorubicin hydrochloride) in DMSO was transferred to each 
well of the assay plate using a pintool (Kalypsys, San Diego, CA), and the plates were 
further incubated at 37°C with 5% CO2 for 24 or 48 hrs. After that, 4 µl of CellTilter-
GloTM luminescent substrate mix (Promega) was added to each well (Supplementary 
Table X). The plate was incubated at room temperature for 15 minutes. The plates were 
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measured on a ViewLux plate reader (PerkinElmer) with a clear filter. The final 
concentration of the compounds in the 5 µl assay volume ranged from 0.5 nM to 46 µM. 
 
2.16 NPC library screening 
The NPC consists of 3,826 small molecule compounds, with 52% of the drugs approved 
for human or animal use by the FDA [92]. The remaining drugs are either approved for 
use internationally (i.e. in Europe, Canada, or Japan), or are compounds that have been 
tested in clinical trials. Additional detailed information on the drug library can be found 
at http://tripod.nih.gov/npc/. 
The compounds from the NPC library were prepared as 15 interplate titrations, which 
were serially diluted 1:2.236 in dimethyl sulfoxide (DMSO) (Thermo Fisher Scientific, 
Waltham, MA) in 384-well plates. The stock concentrations of the test compounds 
ranged from 10 mM to 0.13 μM. The transfer of the diluted compounds from 384-well 
plates to 1536-well plates was performed using an Evolution P3 system (PerkinElmer Life 
and Analytical Sciences, Waltham, MA). Each treatment plate included concurrent 
DMSO and positive control wells and concentration-response titrations of controls, all 
occupying columns 1 to 4. During screening, the compound plates were sealed and kept 
at room temperature, whereas other copies were maintained at −80°C for storage. 
 
2.17 Data analysis 
qHTS data analysis and curve fitting. To determine compound activity in the qHTS assay, 
the titration-response data for each sample were plotted and modeled by a four parameter 
logistic fit yielding IC50 and efficacy (maximal response) values. Raw plate reads for 
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each titration point were first normalized relative to positive control (doxorubicin 
hydrochloride, 100% inhibition) and DMSO-only wells (basal, 0%). Curve-fits were then 
classified by the criteria described [93]. Usually the qHTS screen yielded hits with a wide 
range of potencies and with substantial variation in the quality of the corresponding 
CRCs (efficacy and number of asymptotes), which included samples associated with 
shallow curves or single-point extrapolated concentration responses; these were assigned 
as low-confidence actives. In brief, Class 1.1 and 1.2 were the highest-confidence 
complete CRCs containing upper and lower asymptotes with efficacies ≥ 80% and < 80%, 
respectively. Class 2.1 and 2.2 were incomplete CRCs having only one asymptote with 
efficacy ≥ 80% and < 80%, respectively. Class 3 CRCs showed activity at only the 
highest concentration or were poorly fit. Class 4 CRCs were inactive, having a curve-fit 
of insufficient efficacy or lacking a fit altogether.  
There were a total of 30 plates in the primary qHTS screen, which included 24 plates 
corresponding to the NPC library set and 6 DMSO plates. Compounds from the primary 
qHTS screen were classified into three categories according to the quality of curve fit and 
efficacy. Actives were compounds in curve class 1.1, 1.2, 2.1 and 2.2 curves with 
efficacy higher than 60%; inactives were compounds with class 4 curves; and 
inconclusive included all other compounds including those shallow curves and curves 
with single point activity.  
 
2.18 Determination and quantification of viable cells by flow cytometry 
PC12 cells were plated overnight and incubated with three different concentrations of the 
various drugs for 24 hrs. To determine apoptotic and viable cells, cells were washed with 
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PBS buffer (2mM EDTA, 0.05% BSA in PBS) and stained with 5 µl of 7-AAD 
(BioLegend) for 10 min. Cells were acquired by flow cytometry (MACSQuant Analyzer, 
Miltenyi Biotec) and 7-AAD-negative viable cells (%) were analyzed by FlowJo software 
(Tree Star).  
  
2.19 Murine MTT cell microarray processing and analysis  
Three separate MTT cell samples were prepared according to Affymetrix protocols 
(Affymetrix, Inc.). RNA quality and quantity was ensured using a Bioanalyzer (Agilent, 
Inc.) and NanoDrop (Thermo Scientific, Inc.) respectively. Per RNA labeling, 200 ng of 
total RNA was used in conjunction with the Affymetrix recommended protocol for 
GeneChip 1.0 ST chips. 
The hybridization cocktail containing fragmented and labeled cDNAs was hybridized to 
the Affymetrix Mouse Genome ST 1.0 GeneChip. The chips were washed and stained by 
the Affymetrix Fluidics Station using the standard format and protocols as described by 
Affymetrix. The probe arrays were stained with streptavidin phycoerythrin solution 
(Molecular Probes, Carlsbad, CA) and enhanced using an antibody solution containing 
0.5 mg/ml of biotinylated anti-streptavidin (Vector Laboratories, Burlingame, CA). An 
Affymetrix Gene Chip Scanner 3000 was used to scan the probe arrays. Gene expression 
intensities were calculated using Affymetrix AGCC software. 
Partek Genomic Suite was used to RMA normalize (Robust Multichip Analysis), 
summarize, logtransform the data, and run ANOVA analysis and hierarchical clustering. 
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2.20 Microarray data analysis 
RNA extraction from MTT cells was performed as previously described [90]. RNA 
quality and quantity were ensured using Bioanalyzer (Agilent Technologies, Inc., Santa 
Clara, CA, USA) and NanoDrop (Thermo Scientific, Wilmington, DE, USA) analysis, 
respectively. Samples in triplicate were processed following the recommended 
Affymetrix protocol. Fragmented and labeled cDNA was hybridized onto Mouse 
GeneChip 1.0ST chip arrays (Affymetrix, Santa Clara, CA, USA). Staining of 
biotinylated cDNA and scanning of arrays were performed according to the 
manufacturer’s recommendations. These data are available at the GEO database. Raw 
CEL-files were imported into R statistical package [94] (http://www.bioconductor.org) to 
perform probe set summarization, background subtraction, and quantile normalization 
using the RMA method. Gene-wise Z-score normalization across all samples was applied 
to adjust for technical variation [95]. The replicate correlation was measured to be >0.98, 
and an average of replicates was used for further analysis. 
A subset of patient data that was previously published [96] (GSE 39716) containing 
SDHB mutation samples was used for comparison with MTT cell line expression. Gene 
targets for the drugs tested on MTT cell lines were compiled from databases (NPC, Drug 
Bank and Therapeutic Target Database), and a total of 2129 genes were mapped to 22 
drugs. Datasets from mouse cell lines and SDHB samples were independently scaled to 
Z-scores before merging them. The merged data was subset by the common genes from 
drug targets, with a total of 1753 genes in common.   
Genes corresponding to < 2-fold change between the MTT cell line and SDHB PHEO 
datasets were considered for further analysis. This selection criterion resulted in a list of 
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1440 genes with an overall correlation of 0.86. To evaluate the similarity of drug targets 
between MTT vs. SDHB samples, a Pearson correlation coefficient was computed 
between a set of target genes from each drug with an overall average correlation of 0.8. 
 
2.21 Network construction, visualization and analysis 
Two metabolic models corresponding to different levels of information were constructed. 
One is a general model that contains the 22 tested drugs and their curated target genes 
(Figure 4). The second network derives from the first one, which is based on the top 20 
hub nodes. Network assembling, visualization and determination of statistical parameters 
were performed using Cytoscape v2.8.3 [97]. For functional and topological analysis, 
Reactome FI [98] and cytoHubba, plugins for Cytoscape were used. The Reactome FI 
plugin was designed to find network patterns related to cancer and other types of disease. 
This plugin accesses the Reactome FI network, a highly reliable, manually curated 
pathway-based protein functional interaction network covering close to 50% of human 
proteins, and allows construction of a FI subnetwork based on a set of genes. The 
cytoHubba plugin allows analysis of the topology of interaction networks and 
identification of essential nodes (hub nodes) that may serve as candidates of drug targets 
for developing novel therapies. The subnetwork of these essential nodes may help us get 
a more precise insight into the functions and how they collaborate together. As a measure 
of node importance, eccentricity scores were computed. The eccentricity is a node 
centrality index. The eccentricity of a node v is calculated by computing the shortest path 
between the node v and all other nodes in the graph, then choosing the “longest” shortest 
path (let (v, K) be a path, where K is the most distant node from v). Once this path with 
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length dist(v, K) is identified, its reciprocal is calculated (1/dist(v,K)). By doing that, an 
eccentricity with higher value assumes a positive meaning in terms of node proximity. 
 
2.22 Drug synergism analysis 
For the synergism study we used the CalcuSyn Windows software for dose-effect 
analysis and synergism/antagonism quantification, following the manufacturer’s 
instructions. Drug synergism was determined from median effect analysis equations 
developed by Chou-Talalay [99,100]. Cell proliferation data (MTT assay) were analyzed 
using CalcuSyn software (Biosoft UK). Combination Index (CI) indicates additivity when 
CI = 0.8-1.2; synergism when CI < 0.8; and antagonism when CI < 1.2. The DRI shows 
the potential dose reduction of each single drug in synergistic combination at a given 
effect level achieved by combining these drugs. 
 
2.23 Statistical analysis 
Tumor volume and mean bioluminescence was determined for each experiment together 
with the standard errors of the mean. To illustrate the relationship between 
bioluminescent signal, tumor volume and cell number a regression plot was used. 
Statistical analyses were performed using Graph Pad Prism software, including unpaired t 
test and non-parametric Mann-Whitney test (Graph Pad Software).   
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3. RESULTS 
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3.1  CHARACTERIZATION OF TWO MOUSE MODELS OF METASTATIC 
PHEOCHROMOCYTOMA USING BIOLUMINESCENCE IMAGING. 
 
3.1.1  Generation of stably transduced luciferase expressing MTT cells. 
The generation of aggressive, rapidly growing mouse pheochromocytoma cell line MTT 
from liver metastasis of MPC cells has been previously described [38,85]. For retroviral 
delivery and expression of luciferase in MTT cells, I first generated the construct pLLuc 
via replacement of EGFP with a luciferase gene between the BamH-1 and Not-1 sites of 
the retroviral vector pLEGFP. This construct employs the human cytomegalovirus 
(CMV) immediate early promoter to drive firefly luciferase expression while the 
expression of the neomycin resistance gene is driven by a separate constitutively active 
viral promoter contained within the 5’ LTR. After transfection with the pLLuc and 
selection with G418 of the packaging cell line Amphopak-293, filtered conditioned 
medium from the stably transfected 293-LLuc cells containing retroviral particles was 
used to transduce MTT cells. The infected MTT cells were then selected with G418 for 
four weeks to obtain stably transduced MTT-Luc cells. Quantitation of firefly luciferase 
expression in MTT-Luc cells was done by directly adding a luciferin substrate into the 
culture medium of plated cells. Luminescence was imaged to obtain photon/s per cell 15 
minutes after addition of the substrate. As shown in Figure 1 (panel A), serial dilutions of 
these cells showed a proportional decrease in mean photon emission, with an average of 
200 photons/s per cell, indicating a stable and sustained intensity of the bioluminescence 
signal. These new cell line were names “MTT-luc”.  
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Analysis of covariation between number of cells plated and light intensity (total photon 
flux) showed a highly significant correlation (R2 = 0.995) as illustrated in Figure 1B. 
 
3.1.2  Detection and non-invasive BLI monitoring of MTT-luc cell in an 
experimental metastasis model. 
I then used a tail vein (experimental metastasis) injection of MTT-luc cells to evaluate the 
sensitivity of BLI to detect experimental metastasis after systemic circulation of the 
tumor cells. Mice were imaged immediately after injection to verify the success of the 
procedure and subsequently imaged over time by BLI over a 7-weeks period. BLI Images 
of a representative nude mouse is shown in Figure 2A (upper sequence). In parallel 
animals were subjected to serial MRI. Shown in Figure 2A (lower sequence) are MRI 
images of the same mouse over the same time period. 
The results show that tumor signals increased significantly over the seven weeks of the 
study with exponential growth seen especially localized in the upper abdominal cavity. 
As expected, localized bioluminescent signals indicating metastasis began to appear in 
the area of the liver and were detectable at an early stage of development, starting at the 
second week post-injection. By the third week, several areas of tumor growth were 
evident by both BLI and MRI. Total photon flux from tumors seen in BLI was found to 
correlate well with the number of lesions observed by MRI (Figure 2B). An analysis of 
covariation between number of metastatic lesion as counted on the MRI image and 
bioluminescent light intensity (total photon flux) shows a highly significant correlation 
(R2 = 0.992) as illustrated in Figure 2C. By the 4th week the tumor masses were clearly 
identifiable by MRI. Figure 2D illustrates the progression of tumor size over time from 
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the 4th week represented as a sphere from averaged tumor diameters calculated by MRI 
analysis. The survival curve representation for this model is shown in Figure 2E.  
At necropsy, several organs were excised, imaged ex vivo and preserved for histological 
evaluation. Ex vivo bioluminescence confirmed the presence of MTT-luc metastasis in 
the liver and in several other organs, including lungs, spleen, ovaries, kidney and brain 
(Figure 2F and Table 1). The total photons/sec of the organs were quantified for each 
animals (n = 6) and mean values are displayed in Figure 2F. 
 
 
Table 1. Comparison of number of metastatic lesions in the two animal models 
(metastatic-take). 
 Experimental metastasis 
model 
(tail vein injection) 
Spontaneous metastasis 
model 
(subcutaneous injection) 
Liver 6/6 (100 %) 6/6 (100 %) 
Lungs 6/6 (100 %) 6/6 (100 %) 
Brain 4/6 (66 %) 5/6 (83 %) 
Spleen 6/6 (100 %) 2/6 (33 %) 
Ovary 4/6 (66 %) 4/6 (66 %) 
Kidney 1/6 (16%) 3/6 (50 %) 
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3.1.3  Tumorigenicity and spontaneous metastasis of subcutaneously implanted 
MTT-luc cells. 
To assess the tumorigenicity and tumor growth modality of the MTT-luc cells in 
immunocompromised animals, I injected 1x10^6 cells s.c. into the left flank of 6 week 
old nude mice. The use of luciferase-reporter cells allowed for the immediate detection of 
tumor cells at the time of injection and enabled the detection of cells implanted at various 
sites. The growth of the MTT-luc tumors in the nude mice was monitored over time in 
vivo by bioluminescent imaging. Images at key time points from a representative animal 
are shown in Figure 3A, illustrating the progressive increase in the bioluminescence 
signal over time. Mean photons emitted from the tumors over time and tumor volume in 
figure 3C as assessed by caliper dimensions when the tumors became measurable (by 
week 4) are illustrated in Figure 3B. Notably, the tumor cells were visible by 
bioluminescence imaging much earlier than the tumor became measurable or palpable. 
Analysis of covariation between BMI light intensity (total photon flux) and measured 
tumor volume showed a high degree of  correlation (R2 = 0.99) as shown in Figure 3C. 
Only a few aggressive cell lines have been reported to spontaneously metastasize from 
subcutaneous implantation in the literature. For this reason, at the end of the 7-week 
experiment I wanted to verify if any metastatic MTT-luc tumor cells waere detectable by 
bioluminescence analysis in several organs. Fifteen minutes after luciferin injections, the 
mice were euthanized and several internal organs, including liver, lungs, spleen, ovaries 
and brain, were analyzed for bioluminescence signals (Figure 3D and Table 1 above). 
Indeed, I was able to detect MTT-luc cells in several of these organs. The lungs, which 
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represented the organ most consistently seeded by subcutaneously implanted MTT-luc 
cells, are also a favored site of metastasis of human pheochromocytomas [101]. 
 
3.1.4  Bioluminescence signals correlate with metastatic lesions identified by 
histopathology. 
To confirm the presence of metastatic tumor cells in the main organs targeted in the two 
metastatic models we described, I performed histopathological examination of formalin-
fixed tissues collected after ex vivo imaging. For the experimental metastasis model in 
which tumor cells were injected in the mouse tail vein, the most intense and reproducible 
signals were derived from the livers; indeed, histopathological analyis of livers from 
these animals revealed macro and micro metastasis (Figure 2G, left panel). 
In the second models (subcutaneous injection of tumor cells), histopathological analyis 
confirmed the presence of micrometastasis in the lungs (Figure 3E, right panel), 
consistent with the ex vivo bioluminescence signal. 
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3.2  COMBINED INHIBITION OF MTORC1 AND MTORC2 SIGNALING 
PATHWAYS FOR THE TREATMENT OF PHEOCHROMOCYTOMA. 
 
3.2.1  mTOR, Raptor and Rictor Are Over-expressed in Subsets of 
Pheochromocytomas  
First, I wanted to verify the expression of mTOR, Raptor and Rictor in several tumors 
from our collection of PHEO/PGL from patients with different genetic backgrounds. 
Expression analysis was performed with 20 tumor samples from patients with VHL, 
SDH-B, SDH-B metastases (SDH-B Meta), SDH-D adrenal, SDH-D head and neck PGL 
mutations, and 4 normal adrenal medulla (NAM). Table 2 summarizes the clinical 
information of the patients used for these studies. Expression of the three genes in these 
groups was analyzed by real-time PCR (Figure 4). As shown in Figure 4, patients with 
SDH-B and VHL mutations showed a significant increase (compared to normal adrenal 
medulla) in mTOR expression when compared with the other samples analyzed in this 
panel. Interestingly, both SDH-B and metastatic SDH-B pheochromocytoma showed a 
significant increase in expression of mTOR compared to normal adrenal medulla (p < 
0.05). Analysis of both Raptor and Rictor expression demonstrated a significant increase 
in SDH-B pheochromocytoma tissue when compared to patients in other groups as well 
as the normal adrenal medulla.  
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Table 2: Patients information relative to the samples used for the gene expression study.  
 SEX AGE TYPE LOCATION 
GENETIC 
BACKGROUND BIOCHEMISTRY 
Pt-1 M 26 Met retroperitoneal SDHB  NE, NMN 
Pt-2 F 36 Met peri illiac SDHB  NE 
Pt-3 M 31 P 
left peri-aortic 
mass SDHB  DA 
Pt-4 M 53 Mlt nasopharingeal SDHB  NE, DA 
Pt-5 F 9 Mlt 
left illiac 
bifurcation SDHB Epi, NE, DA 
Pt-6 M 31 Mlt left adrenal SDHD NE, DA 
Pt-7 M 62 P left adrenal SDHD  
Pt-8 F 37 P adrenal SDHD  
Pt-9 F 26 Mlt right carotid body SDHD_HNP NE 
Pt-10 M 67 Bi carotid body SDHD_HNP  
Pt-11 F 47 Mlt carotid body SDHD_HNP  
Pt-12 F 64 P 
right glomus 
jugulare tumor SDHD_HNP  
Pt-13 M 33 
Bi and 
Mlt bilateral adrenal VHL  
Pt-14 F 42 Bi right adrenal VHL  
Pt-15 M 25 P right adrenal  VHL  
Pt-16 M 7 P left adrenal VHL NE, Epi,  
Pt-17 M 45 Met liver SDHB met NE, NMN, DA 
Pt-18 M 39 Met right lung SDHB met NE 
Pt-19 M 48 Met  liver SDHB met NE, DA 
Pt-20 F 37 Met 
parietal bone 
mass SDHB met Epi, NE 
Mlt – multiple; P – primary; Met – metastatic; Bi – bilateral; NE – norepinephrine; NMN – 
normetanephrine; DA – dopamine; Epi – epinephrine; HNP – head and neck paragangliomas. 
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3.2.2  mTORC1/2 Inhibitors Inhibit Pheochromocytoma Cell Proliferation and 
Migration 
Based on the importance of the mTOR pathway in pheochromocytomas and 
paragangliomas, I tested mTOR inhibitors in a proliferation assay using the metastatic 
MPC-derived MTT cell line [38]. As shown in Figure 2, the original mTOR inhibitor 
rapamycin was able to inhibit MTT cell proliferation with an IC50 of 756 nM (Figure 
4D). In comparison, the novel mTORC1/2 inhibitors AZD-8055 and Torin-1 were able to 
significantly inhibit cellular proliferation in a dose-dependent manner in MTT cells over 
a range of concentrations (1nM to 1M) with an IC50 of 96 nM (Figure 4D) and 207 nM 
(Figure 4D), respectively. These data show that rapamycin induces only partial growth 
inhibition, while the dual inhibitors have a much greater suppression of proliferation. 
The effect of mTORC1/2 inhibitors treatment on cell migration was tested in the 
metastatic pheochromocytoma cell line MTT; I found that AZD8055 reduced serum-
stimulated migration (Figure 4E and 4F), with an IC50 of 260 nM. Torin-1 was also able 
to significantly inhibit MTT cell migration, with an IC50 of 400 nM (Figure 4E and 4F). 
Interestingly, MTT cells tended to become confluent in clusters, reminiscent of the 
“zellballen” nested arrangement characteristic of pheochromocytoma histopathology. As 
shown in the micrograph images in Figure 4E, inhibition with either mTOR inhibitor 
reduced the formation of such clusters. 
  
3.2.3  AZD8055 and Torin-1 Treatment Affects mTOR Downstream Signaling 
As a part of the assessment of mTORC1/2 inhibitor activity in pheochromocytoma cells, 
MTT cells were exposed to different concentrations of rapamycin, AZD8055 and Torin-1 
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for 6 hours to assess downstream markers of mTOR kinase activity. Both AZD8055 and 
Torin-1 decreased phosphorylation of S6 ribosomal protein on Ser235/236 and 
Ser240/244, as well as phosphorylation of eIF4B on Ser422. Unlike the allosteric mTOR 
inhibitor rapamycin, the dual inhibitors were also able to significantly decrease 
phosphorylation of Akt on Ser473. Moreover, lower concentrations of AZD8055 and 
Torin-1 were necessary to obtain the same degree of biomarker modulation compared to 
rapamycin (Figure 5). 
 
3.2.4  AZD8055 Reduces Pheochromocytoma Tumor and Metastatic Burden in vivo 
The antitumor effect of AZD8055 was assessed in vivo in a recently-developed 
spontaneous metastasis model of pheochromocytoma [86]. From week 3 through week 7, 
a significant reduction of tumor burden was observed in the AZD8055-treated animals 
(n=7) compared to vehicle-treated animals (n=7; Figure 6A). As previously described 
[86] in the MTT pheochromocytoma model, the two main organs where spontaneous 
metastases develop are the lungs and liver. On day 49, after in vivo bioluminescence 
measurements had been taken, the animals were sacrificed and both lungs and livers were 
excised and luciferase activity was measured by Xenogen imaging. A trend of reduced 
metastatic burden was observed in lungs (Figure 6B) and livers (Figure 6C) of the treated 
animals compared with the control group, although only differences in lung metastasis 
were statistically significant using non-parametric statistics in the time-frame of our 
experiment. 
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3.2.5  AZD8055 and Torin-1 inhibits proliferation of primary cells from patients 
with Pheochromocytoma 
The growth inhibitory effect of AZD8055 and Torin-1 was evaluated in human primary 
cell derived from donated tumor tissue collected from patients suffering from 
pheochromocytoma, including one SDHB tumor. Immunohistochemical staining for 
tyrosine hydroxylase (TH), the rate-limiting step in the biosynthesis of catecholamines, 
was used as a marker of pheochromocytoma cells to discriminate them from other cell 
types that are inevitably present in primary cultures. As shown in Figure 6, AZD8055 
(Figure 6E) as well as Torin-1 (Figure 6F) decreased the number of TH-positive cells to 
50% of control cells, confirming their cytotoxic effect also on human pheochromocytoma 
cells. Table 3 summarizes the clinical information on the patients used for these studies. 
 
Table 3: Patient information of the samples used for primary cell cultures and treatments. 
 SEX AGE TYPE LOCATION
GENETIC 
BACKGROUND BIOCHEMISTRY 
inhibition 
at 1 uM 
AZD8055 
(%) 
inhibition 
at 3 uM 
AZD8055 
(%) 
Pt1 F 44 P right adrenal sporadic 
NE, DA, NMN      
27.1
48.5 
(Torin-1: 
48.2) 
Pt2 F 28 P right adrenal SDHB  
NE, DA, NMN, 
CgA               22.6 68.9
Pt3 F 47 P 
right carotid 
body  sporadic CgA       23.2
                  
-     
Pt4 M 5 P left adrenal  VHL MN, NMN  17.1
51.9 
(Torin-1: 
52.4)
	
Included are the percent inhibition with 1M and 3M AZD8055, and 3M Torin-1. P – primary; NE – 
norepinephrine; NMN – normetanephrine; DA – dopamine; CgA - chromogranin A; MN –metanephrine. 
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3.3  TARGETING HEAT SHOCK PROTEIN 90 FOR THE TREATMENT OF 
MALIGNANT PHEOCHROMOCYTOMA. 
 
3.3.1   17-AAG and ganetespib inhibit pheochromocytoma cell proliferation and 
migration. 
17-AAG significantly inhibited cellular proliferation in a dose-dependent manner in all 
the available pheochromocytoma cell lines, namely MPC (Figure 7A), MTT (Figure 7C) 
and PC12 (Figure 7E) cells over a range of concentrations (1 nM to 1 μM) with an IC50 of 
235 nM, 286 nM and 181 nM, respectively.  Ganetespib also caused significant inhibition 
of proliferation of the three pheochromocytoma cell lines and was more potent than 17-
AAG, with IC50 values of 50 nM, 18 nM, and 28 nM in MPC (Figure 7B), MTT (Figure 
7D), and PC12 cells (Figure 7F).  
 We tested the effect of Hsp90 inhibitor treatment on cell migration in the 
metastatic pheochromocytoma cell line MTT and found that 17-AAG reduced serum-
stimulated migration (Figure 7I and 7J), with an IC50 of 144 nM.  Ganetespib was also 
able to significantly inhibit MTT migration, with an IC50 of 44 nM.  Interestingly MTT 
cells tend to become confluent in clusters, reminiscent of the “zellballen” nested 
arrangement characteristic of pheochromocytoma histopathology.  As shown in the 
micrograph images of Figure 7 (G and H), inhibition with either Hsp90 inhibitor 
markedly reduced the formation of such clusters. 
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3.3.2   17-AAG and ganetespib treatment affects Hsp90 client proteins in MTT cells. 
To better understand the mechanisms of cytotoxicity and growth inhibition by Hsp90 
inhibitors, I treated MTT cells with different concentrations of 17-AAG (Figure 8A) or 
ganetespib (Figure 8B) for 20 hours.  After treatment the levels of two established Hsp90 
clients, HIF-1α and phospho-S473-Akt, were measured by western blotting.  As can be 
seen in Figure 8, 17-AAG reduced the amount of both proteins in MTT cells.  Ganetespib 
demonstrated a similar effect. In addition, I analyzed cleaved PARP by western blot after 
treatment with 17-AAG (Figure 8C) and ganetespib (Figure 8D) in MTT cells.  Cleaved 
PARP increased in a dose-dependent manner, indicating that both Hsp90 inhibitors 
induced apoptosis in MTT cells. 
 
3.3.3 Pheochromocytoma metastasis is inhibited by 17-AAG and ganetespib 
To evaluate the effect of 17-AAG in vivo I employed a tail vein model of metastasis with 
MTT cells stably expressing the luciferase gene (MTT-luc cells).  Mice were imaged 
immediately after injection to verify the success of the procedure (week 0, data not 
shown) and subsequently imaged weekly for five weeks.  Tumor signals increased 
significantly over the six weeks of the study with exponential growth especially localized 
in the upper abdominal cavity (Figure 9A).  Eight days after tumor cell inoculation the 
animals were divided in two groups: one group (17-AAG, n=6) received 60 mg/kg three 
times a week (i.p.); a second group (control, n=6) received vehicle alone (DMSO) on the 
same schedule.  17-AAG significantly reduced the metastatic tumor burden (Figure 9A 
and C) and prolonged survival (Figure 9D, p<0.0001) when compared with the control 
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group, with a median survival of 34 days for the control group and 51.5 days in the 17-
AAG treated group. 
To confirm the engagement of Hsp90 by 17-AAG in vivo, we measured the level 
of Hsp70 in plasma pre- and 6 hours post-treatment with 17-AAG.  It has been reported 
that 17-AAG induces the synthesis of Hsp70 [102,103] and that increases in intracellular 
and plasma Hsp70 can be used as a pharmacodynamic marker of Hsp90 inhibitor 
response [104,105].  Thus, we measured Hsp70 levels in plasma as a biomarker for drug 
activity.  As expected, treatment with 17-AAG increased plasma Hsp70 levels (Figure 
9B), indicative of Hsp90 inhibition in vivo.   
Using a spontaneous metastasis model of pheochromocytoma [86], I injected 1.5 
x 106 MTT-luc cells in the subcutaneous tissue of athymic mice.  After 10 days, allowing 
for tumor cells to engraft, I started treatment with 20 mg/kg ganetespib, in the treated 
group of animals (n=8) and the same volume of vehicle in the control group of animals 
(n=8), on a daily x5, five days out of seven schedule.  I then followed the growth of the 
subcutaneous tumor by bioluminescence detection, weekly, weeks 3 thorough 7, which 
demonstrated a significant reduction of tumor burden over time (Figure 10A).  As 
previously described [86] in the MTT pheochromocytoma model, the two main organs 
where spontaneous metastases develop are the lungs and livers.  On day 49, after in vivo 
bioluminescence measurements were taken the animals were sacrificed and lungs and 
liver were excised and luciferase activity was measured by Xenogen imaging (Figure 10C 
and D).  Metastatic burden was dramatically reduced in lungs and livers of the treated 
animals compared with the vehicle control group.  Primary subcutaneous tumors from 
each of the animals were excised and are shown in Figure 5 (Figure 10B).   
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3.3.4 Inhibition of human pheochromocytoma cells in vitro 
All efforts to establish cell lines from primary human pheochromocytomas and 
paragangliomas have been unsuccessful.  Typically, tumor cells from surgical specimens 
can survive up to three weeks but then senesce and die [106].  To test the effect of 
ganetespib on human primary cell cultures, we used primary cells derived from tumor 
tissue collected from pheochromocytoma patients who were surgical candidates on NIH 
clinical protocol 00-CH-0093.  
Immunohistochemical staining for TH, the rate-limiting enzyme in the 
biosynthesis of catecholamines, was used as a marker of pheochromocytoma cells to 
discriminate tumor from cells of the tumor microenvironment.  As shown in Figure 10E, 
treatment with ganetespib for 10 days, with drug washout and readministration every two 
days resulted in a dose-dependent decrease in pheochromocytoma cell number. 
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3.4 DRUG REPOSITIONING HIGH-THROUGPUT SCREENING FOR THE 
IDENTIFICATION OF NEW THERAPEUTIC OPTIONS FOR METASTATIC 
PHEOCHROMOCYTOMA AND PARAGANGLIOMA. 
 
3.4.1  High-throughput screening (HTS) of the NPC Library 
I screened the NIH Chemical Genomic Center Pharmaceutical Collection of clinically 
approved drugs, which contains 1,760 US FDA approved drugs, 785 drugs approved by 
other countries, 1,225 compounds in clinical trials and 56 bioactive molecules, employing 
a model of metastatic PHEO (by using MTT mouse PHEO cells), the most common 
tumor of the adrenal medulla.  
The assay, in a 1536 HTS plate format, measured cell viability by determining 
metabolically active cells (viable cells) in culture using a luciferase, ATP-dependent 
readout (as described in Material and Methods), at two different time points of compound 
incubation (24 hrs and 48 hrs). A number of compounds showed significant cell killing, 
with potency below 10 M (at 48 hrs, when the compounds showed to be more potent 
and efficacious). Compounds were tested at 8 doses using a quantitative HTS (qHTS) 
approach [93]. 
The qHTS identified 76 high-confidence active compounds with curve class (CRC) 1.1, 
1.2, 2.1 and 2.2 [93], with the maximal inhibition over 60%, 3481 inactive and 269 
inconclusive compounds with lower confidence CRC or showing low efficacy in the 
MTT cell line. Of the 76 high-confidence actives, 40 had efficacy higher than 60% and 
potency below 10 µM, which corresponded to a 1% hit rate from the qHTS screening. 
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Five compounds showed significant cell killing effect with potency less than or equal to 1 
µM: the protein synthesis inhibitor and antileukemic (induces apoptosis) drug 
homoharringtonine (IC50 = 0.24 µM); the tubulin inhibitors colchicine (IC50 = 0.47 µM), 
nocodazole (IC50 = 0.53 µM) and fenbendazole (IC50 = 1 µM); and the proteasome 
inhibitor bortezomib/velcade (IC50 = 0.59 µM). Then I performed an enrichment analysis 
into therapeutic categories of the compounds obtained from the primary screening. I 
identified that the top 5 enriched drug categories active in MTT cells were antiseptic, 
antimalarial, antineoplastic, estrogen and anthelmintic agents (Figure 11). However, these 
categories also represented the ones with fewer compounds, so, relatively, the two major 
categories with the most hits were represented by antineoplastic and antiseptic drugs. 
Top-ranked hits (50 compounds) based on the CRC, efficacy and potency are reported in 
Table 4.  
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Table 4. Top-ranked compounds (hits) with high confidence antiproliferative activity in 
MTT PHEO cells. The table illustrates the drug name, efficacy, IC50 (in µM) and curve 
class. 
 
Sample Name Curve Class IC50 (µM) Efficacy (%) 
Colchicine1 (Colcrys™) -1.1 0.47 -85 
Dipyrithione (Crimanex™) -1.1 1.50 -81 
Zinc pyrithione -1.1 2.11 -91 
1-Hydroxypyridine-2-thione zinc salt -1.1 2.11 -96 
Mersalyl sodium -1.1 2.66 -92 
Auranofin (Ridaura™) -1.1 2.66 -87 
Thimerosal4 -1.1 2.99 -87 
Deslorelin acetate (Suprelorin™) -1.1 2.99 -89 
Paclitaxel1 (Abraxane™, Onxol™) -1.2 0.04 -51 
5-Aza-2'-deoxycytidine, Decitabine2 (Dacogen™) -1.2 0.07 -52 
Homoharringtonine -1.2 0.24 -74 
Trimetrexate glucuronate5 (Neutrexin™) -1.2 0.38 -51 
Rubitecan2 (Orathecin™) -1.2 0.42 -55 
Nocodazole1 -1.2 0.53 -60 
Fenbendazole1 (Panacur™) -1.2 1.01 -61 
Artemisinimum -1.2 1.33 -60 
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Carmofur (Mifurol™) -1.2 1.88 -57 
Suberoylanilide hydroxamic acid2 (SAHA) (Zolinza™) -1.2 2.37 -59 
Tenovin-1 -1.2 2.66 -56 
Carubicinum2 -1.2 2.99 -59 
Captan4 -1.2 2.99 -66 
Lissamine green B -1.2 6.68 -54 
Mycophenolic acid (CellCept™, Myfortic™) -2.1 1.14 -97 
Tyrothricin4 -2.1 1.50 -84 
Mycophenolate mofetil -2.1 1.68 -92 
Brilliant Green4 -2.1 1.68 -108 
Rotenone5 -2.1 2.66 -124 
Lestaurtinib -2.1 2.66 -83 
Ciclopirox ethanolamine -2.1 4.53 -85 
RTA 402 -2.1 6.68 -108 
Sanguinarine -2.1 8.41 -88 
Proflavine hemisulfate2 -2.1 8.41 -92 
Parthenolide -2.1 8.41 -104 
Bortezomib5 (Velcade™) -2.2 0.60 -75 
Albendazole1 (Albenza™) -2.2 0.72 -58 
Sobuzoxane2 (Perazolin™) -2.2 0.84 -56 
Azacitidine2 (Vidaza™) -2.2 1.33 -71 
Tiquizium bromide -2.2 1.88 -52 
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Flavopiridol hydrochloride hydrate -2.2 1.88 -71 
Ancitabina -2.2 2.37 -68 
Ethaverine hydrochloride -2.2 3.60 -60 
2,2',4'-Trichloroacetophenone -2.2 3.76 -71 
Berberine chloride -2.2 4.22 -54 
17-Allylamino-geldanamycin (17-AAG) -2.2 4.22 -81 
Proguanil hydrochloride5 -2.2 4.53 -60 
Topotecan hydrochloride2 (Hycamtin) -2.2 4.73 -90 
Phenelzine sulfate -2.2 5.08 -53 
Oxapium iodide -2.2 6.68 -60 
Methyl violet4 -2.2 7.50 -70 
Malachite Green Oxalate -2.2 8.41 -61 
 
Legend: 1Anti-tubulin agents; 2Drugs targeting DNA and nucleotide analogues; 3proteasome inhibitors; 
4antimicrobial agents; 5antimetabolite. 
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3.4.2 Secondary screening of selected drugs 
The top 50 drugs considered active compounds based on the primary screening were 
grouped and mostly classified in 5 main functional categories: 1) antitubulin agents; 2) 
drugs targeting DNA and nucleotide analogues; 3) proteasome inhibitors; 4) 
antimicrobial agents; 5) antimetabolite. I found that antitubulin agents, which have a 
prominent class effect on protein polymerization and mitotic spindle organization, were 
the drug category with the most entries in the top compounds in the high-confidence list 
(five entries, which included colchicine, paclitaxel, and several –azoles drugs). Another 
class effect was represented by topoisomerase inhibitors (including carubicinum, 
rubitecan, sobuzoxane and topotecan), which have a prominent effect on DNA replication 
and telomerase maintenance. 
A representative selection of compounds from the categories described above were 
selected for further investigation and validated in additional assays to confirm the activity 
of the hits from the HTS screen. For the secondary assays, I took advantage of a 
traditional proliferation assay, namely the colorimetric MTT assay, and a flow cytometric 
analysis for viable cells after drug treatment. I used three different PHEO cell lines, 
namely PC12, MPC and MTT cells (see Material and Methods for a complete 
description). All the compounds tested produced dose-response curves in all three cell 
lines, and were potent compounds having IC50 values in the low nanomolar range (Figure 
12 A-I). 
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To further validate the activity of the selected compounds, I performed a flow cytometry 
cell viability assay using 7-AAD after overnight treatment with the selected compounds 
(Figure 12J). In addition, a Western blot assay was used for detection of PARP cleavage 
(Figure 12K) in MTT cells after 20 hr treatment. The results from both assays from two 
different cell lines confirmed the activity of several antitubulin agents, including 
colchicine, taxol and nocodazole. Other compounds with dose-related activity included 
the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA), the tyrosine kinase 
inhibitor lestaurtinib (which is an inhibitor of FLT3, JAK2, TrkA, TrkB and TrkC) and 
the topoisomerase inhibitor rubitecan. Furthermore, the Hsp90 inhibitor 17-AAG showed 
activity, confirming previously published results [107]. 
 
3.4.3 Microarray data analysis and metabolic model. 
Because the primary and secondary screening was performed in murine cell lines (due to 
the unavailability of human PHEO cell lines), a strategy using microarray data from 
murine and human samples was used to further select a clinically relevant set of drugs 
from our data that could be potentially developed in human clinical trials. I first compiled 
a list of genes directly targeted by the top drugs discovered by the primary screening 
using the NPC library databank. Compounds for which information on specific targets 
was not available were excluded from the analysis. Based on the list of genes compiled, I 
selected a subset of microarray data from a new murine MTT cell microarray and a 
published human SDHB microarray. In particular, I focused on the human microarray of 
patients with SDHB disease, as these patients are the ones that can benefit the most from 
the discovery of novel therapies. To extrapolate the murine screening data for clinical 
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relevance, for each drug I measured the Pearson correlation coefficient between the target 
genes and the expression profiles from these two microarray data sets (Figure 13A). This 
analysis allowed us to bridge and relate the data from the murine screening with the data 
from an available human PHEO expression profile [96].  
 
Two metabolic models were constructed with compounds and targets that have been 
compiled from the data set. The first model was constructed as a complete hypothetical 
network for visualization of the network assembly of 22 compounds tested on the MTT 
cell line. It contained 2153 nodes and 3091 edges (Figure 13B). All targets of a given 
drug were connected to all other drugs, generating a network from which maximum 
connected nodes can be visualized. Using eccentricity scores, a list of the top 20 targets 
was identified (Table 5) that were predicted to be biologically relevant. Functional 
enrichment analysis using Reactome Functional Interaction (FI) identified 406 gene 
ontology (GO) biological categories (p < 0.05). Interestingly, the HDAC inhibitor SAHA 
(vorinostat) was one of the compounds with the highest correlation (Figure 13A) between 
MTT cells and human PHEO/PGL samples based on the gene profile. The second 
network was constructed using targets associated with GO categories (DNA replication 
and histone deacetylation) corresponding to two of the top hub nodes: topoisomerase and 
histone deacetylase, respectively. This subnetwork (Supplementary Figure 13C and D) 
contained 55 nodes and 99 edges and included 5 of the 22 drug targets. Based on 
eccentricity analysis, carubicinum, rubitecan and colchicine (Table 6) were found to have 
a greater influence on the subnetwork.  
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Table 5.  
Rank Name Score 
1 TP53 0.24919 
1 PARP1 0.24919 
1 HDAC2 0.24919 
1 SUMO1 0.24919 
1 APAF1 0.24919 
1 TOP2A 0.24919 
1 CDKN1A 0.24919 
1 CASP9 0.24919 
1 CDK1 0.24919 
1 MAPK8 0.24919 
1 HDAC1 0.24919 
1 MAPT 0.24919 
1 POLR2A 0.24919 
1 FGF1 0.24919 
1 CASP3 0.24919 
1 RAD51 0.24919 
1 EGFR 0.24919 
1 BIRC5 0.24919 
1 MDM2 0.24919 
1 MAPK1 0.24919 
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Table 6.  
Rank Name Score 
1 Carubicinum 0.33333 
1 Rubitecan 0.33333 
1 Colchicine 0.33333 
4 LIG4 0.25 
4 17-Allylamino-geldanamycin 0.25 
4 KRT7 0.25 
4 TOP1 0.25 
4 HDAC9 0.25 
4 SSRP1 0.25 
4 CHEK1 0.25 
4 RAD9A 0.25 
4 CDC25C 0.25 
4 HMGB2 0.25 
4 HDAC2 0.25 
4 HDAC6 0.25 
4 RMI1 0.25 
4 Flavopiridol hydrochloride 
hydrate 
0.25 
4 EGF 0.25 
4 TYMS 0.25 
4 RFC4 0.25 
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3.4.4 An example of drug combination with synergism analysis 
The compiled list of drugs derived from the screening represented a useful selection of 
compounds with the potential to work effectively in the treatment of metastatic 
PHEO/PGL, either as single drugs or in combination. Moreover, the combined analysis 
of the drug screening and the microarray data sets suggested possible drug combinations 
that are supported by sporadic, but useful, reports in the literature on similar drugs or 
drug categories in the treatment of metastatic PHEO/PGL patients. 
The subnetwork represented in Figure 13C and D constitutes a potential source of 
relevant drug combinations because of the potential biological relationship between any 
of two nodes in the network. As an example, I selected for study the combination of the 
HDAC1/2 inhibitor SAHA and a structural analogue of carubicinum, namely epirubicin, 
which is a more clinically relevant compound based on the reported use in therapeutic 
combination for PHEO [108] and for other tumors [109]. I combined epirubicin with 
SAHA at a constant ratio (1:200) in doses approximately equal to their IC50 and also in 
concentrations equally distributed above and below the relative IC50s. For this reason I 
first determined the relative IC50 for each single compound: 1 uM for SAHA and 5 nM 
for epirubicin (Figures 14A and B). As shown in Table 7 and Figure 14C (median-effect 
index) and D (algebraic estimate of the combination index), this combination produced a 
synergistic effect at all concentrations tested. The benefits of combining these two drugs 
were seen in the dose reduction index (DRI), as described in Materials and Methods. 
Reducing the concentration of a single drug when given in combination may lead to a 
reduction of the side effects of each drug. This strategy represents a promising approach 
to test potentially clinically useful combinations, using a combination of traditional qHTS 
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screening testing with innovative microarray analysis. 
 
 
Table 7.  Combination of SAHA and epirubicin in MTT cells. CI = Combination index. 
DRI = Dose reduction index. 
 
IC50 folds 
EPI/SAHA 
[µM] 
Fraction 
Affected 
CI Effect 
DRI 
EPI/SAHA 
4x 20/4000 0.808566317 0.719 Synergistic 8.227/1.674 
2x 10/2000 0.740589432 0.537 Synergistic 8.593/2.378 
1x 5/1000 0.588437471 0.568 Synergistic 5.459/2.6 
0.5 2.5/500 0.446667935 0.553 Synergistic 4.23/3.156 
0.25 1.25/250 0.328056979 0.518 Synergistic 3.675/4.069 
 
 
 
 
 
 
 
 
 
77	
	
 
 
 
 
 
 
 
 
 
 
 
4. DISCUSSION AND CONCLUSIONS 
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The treatment of rare tumors represents a major challenge in oncology. In particular, 
neuroendocrine tumors, such as pheochromocytomas and paragangliomas, are rare 
tumors for which there are very limited therapeutic options [1,71]. Malignant 
pheochromocytomas have been historically very difficult to treat, as traditional 
chemotherapy has been mostly unsuccessful and data from clinical trials are difficult to 
interpret due to the low prevalence of the disease and the inability to recruit in the same 
trial an adequate number of patients [110]. 
 
However, the study of the molecular determinants of pheochromocytoma tumorigenesis 
has suggested a handful of potential targets to explore with novel targeted therapies, 
which have already demonstrated successful treatment for other forms of cancer [111]. 
Currently, there is increasing interest in the pheochromocytoma research community to 
seek novel targeted therapies which have predominantly a cytostatic effect by interfering 
with a specific molecular target needed for carcinogenesis and sustained tumor growth 
[110,112,113]. 
 
We used the following cell lines, which represent the only available permanent PHEO 
cell lines available to the scientific community and include a range of models of PHEO. 
The rat PHEO cell line PC12, developed in 1976, has a MAX gene deletion that has been 
recently discovered in a human PHEO kindred [40]. The mouse MPC cell line, derived 
from NF1 knock-out mice, represents a well differentiated model, with a behavior very 
similar to most slow-growing PHEO/PGL; interestingly, recent evidence points to NF1 
loss of function as a frequent occurrence in sporadic PHEO [114]. Finally, the MTT cell 
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line, which is rapidly growing and derived from the liver metastases of MPC cells, is a 
model related to some more aggressive human PHEO/PGL, with accelerated metastatic 
behavior [38].  
 
Bioluminescence has been used for the detection of primary tumor growth and 
tumor metastasis in animal models of several tumors, but, to our knowledge, this is the 
first report on the use of bioluminescence in animal models of pheochromocytoma. The 
use of this technology allow for the non-invasive and real-time assessment of tumor 
burden in the same group of animals over time [115]. This type of model is particularly 
well suited for the evaluation of efficacy of novel therapy and it has been developed with 
the intent to create a platform for the pre-clinical evaluation of new targeted therapy for 
pheochromocytoma. 
Previous studies in our group have established a metastatic model of 
pheochromocytoma by mouse passages of the murine pheochromocytoma cell line MPC 
[38]. Through disaggregation and culturing of liver tumor metastasis, we established the 
MTT cell line, which display a reproducible metastatic phenotype when injected 
intravenously. In order to follow the localization of these cells in the intact animal 
longitudinally, we generated a bioluminescent MTT cell line and compared the 
bioluminescent signal with serial MRI imaging.  
In our study we demonstrated a strong correlation between the detection of 
photons and the radiologic examination. BLI offers several advantages over more 
traditional radiologic techniques, such as MRI and CT scanning, which require long scan 
times and expensive instrumentation. Bioluminescence offers a signal with practically no 
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background, as other source of significant bioluminescence are absent in mammals, and 
the light generated easily penetrate mammalian tissues and can be detected by sensitive 
charge-coupled device (CCD) cameras and quantified more precisely by the conversion 
of the luminescence signal into a digital value. This is in contrast with the use of 
fluorescent tags, that require an excitation signal (which penetrate  tissue layers with 
difficulty), and are limited by the presence of tissue autofluorescence and 
photobleaching. Moreover, the luciferase gene can be stably integrated into the 
chromosomes of target cells, and so carry over subsequent cell divisions and not lost over 
time. 
Luciferase-transfected cells can be easily monitored in virtually any location in 
the body, including sanctuary sites, where only a few cells are sufficient to generate a 
detectable signal that would be undetectable by MRI or CT scanning; thus, it is by far the 
most sensitive of the noninvasive technique. Consequently, among the several imaging 
techniques available for in vivo studies, bioluminescence is the more sensitive to detect 
minimal residual disease, which is one of the more daunting and elusive entities in 
clinical oncology. 
Moreover, BLI can represent quantitatively the amount of viable tumor cells in 
the body, allowing comparison not only within the same experiment but also across 
several experiments. The ability to non-invasively track the growth of tumors and 
metastasis in vivo also permit a better understanding of the mechanism of cancer 
development and intervention. Several investigations in other type of cancers have 
already demonstrated the power of BLI in longitudinal therapy intervention studies for 
the follow-up of tumor growth after treatment with experimental drugs [116]. In these 
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types of studies the BLI signal in the animal injected with tumor cells is determined prior 
to intervention with the drug of interest to establish a reference/starting measurement. 
Subsequent scanning are then normalized relative to the reference signal in the same 
animal and differences are calculated between the control group (receiving vehicle alone) 
versus the group receiving the tested drug.  
We have also established a spontaneous metastasis model of pheochromocytoma, 
in which cells from a subcutaneous implant send micrometastases to the lungs. These 
models are rare in the literature, and represent a unique opportunity to explore steps of 
the metastatic cascade that are not testable in an experimental metastasis model [117]. 
Indeed, spontaneous metastasis spread following a natural mechanism of invasion of the 
surrounding tissue, and allow the examination of all steps of the metastatic cascade. This 
model could in particular be more clinically relevant, when testing for drugs that target 
more advanced disease stages. For example other groups using a spontaneous metastasis 
model of the breast cancer cell line MDA-MB-435 [118] was able to demonstrate the 
responsiveness of metastasis to therapies that were initially found to be ineffective in the 
treatment of the primary tumor. On the same line other groups have successfully used 
these animal models for testing novel molecular targeted therapies [119]. 
Beside the study of intact animals along the course of the study, ex vivo analysis 
at the end of the experiments allows for additional important information to be collected 
from the same animal. Namely, ex vivo bioluminescence can help to identify very small 
metastatic lesions that are not easily detectable by in vivo imaging, more accurately 
assessing metastatic burden. For example, while it was relatively easy to detect signals 
from the abdominal cavity, brain lesions were undetectable by both MRI imaging and in 
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vivo BLI. In contrast, ex vivo BLI was able to promptly detect a small number of tumor 
cells that crossed the blood-brain barrier causing micrometastatic brain disease.  
A technical point of interest was that we were able to use G418 to exert selective pressure 
on transduced MTT cells. This was somewhat unexpected because the primary tumor 
from which MPC and MTT are derived arose in a Nf1 knockout mouse generated by 
insertion of a neomycin resistance gene in reverse orientation into the Nf1 gene [120] and 
the original MPC line was intrinsically G418-resistant (JF Powers, unpublished). The 
apparent loss of intrinsic resistance might have resulted from somatic recombination, a 
possibility that itself has implications for design of targeted cancer therapy. 
In summary, the experiments on the animal models demonstrate the ability of 
bioluminescent imaging to follow the progression of pheochromocytoma cells in live 
animals in order to study the course of tumor progression and to test clinically relevant 
antitumor treatments in in a mouse model of metastatic pheochromocytoma. The sites of 
metastasis in this model are also favored for metastases of human pheochromocytomas 
[101]. No comparable human cell-based model currently exists. 
 
A significant number of pheochromocytomas is associated with familial etiology, and can 
be included in familial syndromes such as von Hippel-Lindau (VHL), multiple endocrine 
neoplasia type 2 (MEN2), neurofibromatosis type 1 (NF1) and SDH mutation-related 
tumors (4). VHL and SDH-related tumors in these cases seem to share the same 
tumorigenic pseudohypoxia/angiogenesis pathways. There are currently no human cell 
lines available for these tumors, hindering the testing of novel drugs in vitro. 
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Molecular profiling studies have identified ten germline mutations that cause 
hereditary pheochromocytoma and paragangliomas [121,122].  It has been suggested that 
these mutations can be divided into distinct molecular pathways causing errors in the HIF 
hypoxia-driven pathway (VHL, SDHB and SDHD) and errors in RNA synthesis and 
metabolism (RET, NF1, MAX, and TMEM127), while KIF1BBeta is thought to impact 
both pathways [123,124].  VHL targets HIF to the proteasome under normoxic conditions 
and loss of VHL results in HIF overexpression and angiogenesis [123].  SDHB and 
SDHD mutations result in accumulation of succinate, which inhibits HIF prolyl 
hydroxylation, and in the absence of prolyl-hydroxylated HIF VHL cannot recognize HIF 
and target it for degradation, and thus HIF is overexpressed via a different but 
complementary mechanism from VHL mutation [125].   
 
Hereditary pheochromocytomas and paragangliomas can be divided into two clusters 
based on the transcription profile revealed by microarray analysis. Cluster 1 includes the 
tumors with VHL and SDHx mutant genes, cluster 2 involves tumors with mutations in 
RET and NF1 genes [9,10]. Sporadic tumors were surprisingly represented in both 
clusters [126]. As further genes were discovered, additional microarray studies were 
performed in order to classify them into these two clusters. Mutations in KIF1Bb, 
TMEM127 and MAX genes were clustered with RET/NF1 [11]. RET and NF1 mutations 
lead to activation of the RAS/RAF/MAPK and the PI3K/Akt/mTOR signaling pathways. 
TMEM127 mutant tumors cluster with the RET/NF1 group and they enhance mTOR 
activity independent of the above two kinase pathways. Microarray expression analysis of 
KIF1Bb mutant tumors also groups them with tumors associated with RET/NF1 
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mutations, though a potential role of the mutation in kinase pathways is not yet known 
[11]. On the other hand, a recently discovered MAX gene mutation, which leads to 
dysregulation of the MYC-MAX-MXD1 network, is grouped with this cluster for its 
connection with mTOR pathway [25]. Conversely, SDHAF2 and SDHA mutations, 
recently described, can be clustered with SDHx/VHL [11]. 
 
Identification of a unifying player in tumor cells with deregulated energy metabolism and 
altered redox balance is required in order to elucidate molecular mechanisms associated 
with these discrepancies. Several pieces of experimental evidence indicate a potential role 
for the PI3K/Akt/mTOR pathway. Recently identified mutations in the TMEM127 gene 
have confirmed the importance of this pathway in the pathogenesis of 
pheochromocytoma [127] and further stress the importance of studying the molecular 
pathways downstream of susceptibility genes in expanding our understanding of the 
disease [1,6]. Elevated levels of the phosphorylated form of S6K1 were observed in both 
cluster 1 and cluster 2 tumor samples with more significant increases in cluster 2 tumors. 
Such results further support an important role for the mTOR pathway in PHEO/PGL 
[128].  
 
The work presented has shown that the dual mTORC1 and mTORC2 inhibitors 
AZD8055 and Torin-1 were able to block proliferation in our mouse pheochromocytoma 
cell line, and were more effective than the pure mTORC1 inhibitor rapamycin. The 
Western blotting studies confirmed inhibition of the targets downstream to mTOR, but 
additionally the dual inhibitors decrease Akt phosphorylation. We have previously 
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demonstrated increased levels of activated Akt in a model of pheochromocytoma induced 
by ectopic expression of ErbB-2 [129], in conjunction with reduction of the PTEN 
protein, consistent with other experimental work [130]. These experimental studies 
reinforce the importance of the pathway. 
The dual inhibitors also blocked cell migration. These results translated to the in vivo 
situation in our transplanted athymic mice. Finally, we were able to use small number of 
human tumors to show cell loss induced by the inhibitors. Thus, it would appear that the 
dual TORC1/2 inhibitors may offer a novel and effective therapy for 
phaeochromocytomas and paragangliomas with invasive and/or malignant characteristics, 
and it is worth considering their use in the clinical situation.  
 
Of note, all efforts to establish cell lines from human pheochromocytomas and 
paragangliomas have been unsuccessful because the cells survive but do not proliferate in 
vitro [106]. For this reason we used first passage primary cell cultures from patients with 
pheochromocytoma to access the effect of AZD8055 on human samples. Tyrosine 
hydroxylase (TH), a marker of catecholamine producing cells, was used to distinguish 
pheochromocytoma cells from non-neoplastic fibroblast and other cell types in the 
primary cell culture. 
 
Our results suggest that dual inhibition of mTORC1 and mTORC2 [131] is a potential 
novel therapeutic approach for patients with pheochromocytoma and may overcome the 
problem encountered with the use of mTORC1 inhibitors alone [84,132]. Future efforts 
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will be directed towards using these compounds in combinations with other 
chemotherapeutic drugs or novel targeted therapies. 
 
Progress in the treatment of malignant pheochromocytomas has been limited, in part 
because of the rarity of this malignancy, the lack of sensitivity to cytotoxic therapy, and 
the anecdotal nature of responses to therapy reported in small case studies or very limited 
numbers of patients in larger clinical trials [1,71]. The genetic characterization of 
pheochromocytoma has indicated that targeting angiogenesis with small molecule or 
monoclonal antibody antiangiogenics may present a rational therapeutic strategy for 
metastatic pheochromocytoma patients [128].  The molecular characterization of 
hereditary pheochromocytoma is also supported by data indicating that VEGF is 
overexpressed in the majority of paragangliomas and pheochromocytomas.  Moreover, 
pheochromocytomas and paragangliomas are often hypervascular, both radiographically 
and at resection [133,134], and VEGF expression and increased microvessel density are 
associated with an aggressive phenotype [135,136].  Interestingly, in a study of familial 
and sporadic pheochromocytomas and paragangliomas VEGF, hypoxia-inducible factor-
1α and hypoxia-inducible factor-2 α (HIF-1α and HIF-2α) were prominently expressed in 
both tumor cells and in endothelial cells lining tumor blood vessels, and VEGF and HIF-
1α and HIF-2α were more highly expressed in familial versus sporadic tumors.  These 
data, together with transcriptional profiling analyses [137], are consistent with a 
pseudohypoxic angiogenic drive in the pathogenesis and progression of malignant 
pheochromocytoma and paraganglioma (Favier J et al Endocr Pathol 2012).  
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Our data showing downregulation of HIF-1α protein by Hsp90 inhibition, 
together with the Hsp90 inhibitor-induced cytotoxicity demonstrated here, are consistent 
with hypoxia as a critical adaptive response promoting survival in these tumors.  In this 
context, Hsp90, a central player in several oncogenic signaling pathways that promote 
angiogenesis, tumor cell survival in low-oxygen conditions and unlimited growth, is a 
rational target for pheochromocytoma.  Moreover, the development of inhibitors of this 
protein in pheochromocytoma is further supported by the knowledge that Hsp90 is 
overexpressed in malignant pheochromocytoma when compared with benign disease 
[1,71,138].  
Hsp90 chaperones hundreds of intracellular proteins [139-141] 
(http://www.picard.ch/downloads/Hsp90interactors.pdf ) and regulates the activity of a 
broad range of signal transduction pathways.  Among these proteins are important 
elements of survival signaling networks including the PI3K/Akt pathway.  In our study 
we have demonstrated the activity of the Hsp90 inhibitors 17-AAG and ganetespib in 
reducing expression of Hsp90-dependent phospho-Akt [142,143].  It is thus of interest 
that levels of phospho-Akt are reported to be increased in pheochromocytoma compared 
to normal adrenal tissue [129]. 
 Clinical experience has demonstrated that targeted therapies can elicit the 
formation of secondary mutations in target molecules, leading to formation of drug 
resistance [144].  The critical role of Hsp90 in the maintenance of several oncogenic 
drivers, represents an additional rationale for the use of Hsp90 inhibitors to eradicate 
cancer cells that have developed resistance to other targeted therapies. 
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Moreover, the capacity of Hsp90 inhibitors, such as 17-AAG and ganetespib, to interfere 
with several survival and resistance signaling pathways make them attractive drugs for 
combination therapy.  Indeed, the inhibition by these drugs of multiple oncogenic 
signaling cascades [145] can overcome pathway redundancy and sensitize cancer cells to 
other chemotherapeutic compounds [146,147]. 
            Examination of the effect of treatment with 17-AAG in intact animals showed an 
increase in Hsp70 blood levels, demonstrating that the dose used in our experiment 
achieves biologically active plasma concentrations and affects its target.  This is in 
agreement with other studies [104,105]. Rajan et al. [148] have shown a statistically 
significant correlation of Hsp70 protein levels in peripheral blood mononuclear cells with 
pharmacokinetic parameters.  While Hsp70 up-regulation is a clear indication of 
biological activity, its usefulness as a clinical biomarker for Hsp90 inhibitor therapy 
remains to be explored.  Hsp70 is thought to promote survival of normal and tumor cells 
in response to cellular insults, and this prosurvival activity may contribute to therapy 
resistance (Wissing, Li et al. 1992).  Future therapy involving Hsp90 inhibitors will be 
likely in combination with other therapeutics, and Hsp70 induction will provide guidance 
for dose selection.   
 The metastatic mouse model using highly metastatic MTT cells that was recently 
developed as described above can be used for testing drugs for advanced metastatic 
disease [86].  Although other animal models of pheochromocytoma have been described 
(and recently reviewed by Korpershoek et al. [149]), only three have been reported to 
have pheochromocytoma metastasis in lungs and pelvic nerve.  However our model has 
the advantage of reproducibly obtaining metastases in 100% of animals, and offers the 
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advantage of monitoring tumor burden and tumor metastasis over time via non-invasive 
bioluminescence imaging [86].  Targeted anticancer drugs that have excellent activity in 
vitro and in subcutaneous models of in vivo tumor growth are rarely analyzed for activity 
in metastatic models, and can have markedly more limited activity or even growth-
promoting activity in the metastatic milieu.  The failure to test targeted therapy in 
orthotopic or metastatic models, as well as immunocompetent models, may contribute to 
late stage failure in drug development.  Although the in vivo model used here is not in an 
immunocompetent host, it is a model of metastatic disease with measurable tumor growth 
in lung and liver, which along with bone and lymph nodes represent two of the four sites 
most observed in human disease.  In this context, the first generation Hsp90 inhibitors 
have been shown to be very active against subcutaneous xenografts but to increase 
growth of prostatic and breast carcinoma cells in bone.  In contrast, the second-generation 
inhibitor SNX-5422 had activity against both subcutaneous and bone tumor.  Here we 
have used two different Hsp90 inhibitors, 17-AAG and ganetespib for in vivo studies, and 
demonstrated dramatic antitumor activity against both subcutaneous and metastatic tumor 
growth.   
In our experiments using primary human cell cultures, we observed a dose-
dependent reduction in tumor cells after treatment with ganetespib, further emphasizing 
the efficacy of this compound on pheochromocytoma  tumor cells.  In conclusion, our 
study supports the inclusion of pheochromocytoma and paraganglioma  in the list of 
indications that can potentially benefit from Hsp90-directed therapy. 
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From an industry perspective, drug development programs for rare (“orphan”) diseases 
such as PHEO/PGL (approximately 1,000 new cases are diagnosed in the US each year) 
are less appealing because of the low return on investment. Thus, alternative approaches 
must be sought to discover novel therapeutic options for these tumors. One potential 
strategy is to “recycle” drugs that have been approved for use in the treatment of other 
diseases, a strategy known as drug repurposing or repositioning [150-152]. Drugs that 
received regulatory approval have already proven to be safe and effective for a particular 
disease. In addition, historical information regarding their pharmacokinetics, 
pharmacodynamics and long-term side effects in a large population is available, which 
makes repurposing for other diseases less time-consuming and expedites their 
introduction into clinical trials that are very much needed. Of particular concern are 
patients carrying mutations in the SDHB gene, as these patients are more prone than 
other patients to develop more aggressive and metastatic disease [153,154]. 
 
HTS of chemical libraries is a powerful generator of potentially clinically useful 
compounds to treat metastatic PHEO/PGL. This approach is novel for the field of 
PHEO/PGL, which is now experiencing a renaissance of interest in drug discovery, in 
particular in the evaluation of novel targeted therapies, especially following the discovery 
of several novel gene mutations (and consequently several intracellular signaling 
pathways with potential cellular targets) predisposing to the disease [155]. 
 
Compared with other cancer types, one of the major challenges in the development of 
novel therapeutics for metastatic PHEO/PGL is the absence of bona fide human cell lines 
91	
	
for cell-based preliminary testing; viable and functionally active primary cells can be 
obtained from donated tumor tissue but unfortunately do not proliferate [106]. For this 
reason we used an alternative approach to extract clinically useful information by 
crossing and combining data from our primary qHTS drug screening with information 
available about the expression profiles of a murine and a human microarray data set. Of 
note, however, the cell lines we used in our assays represented viable models of PHEO. 
For example, the recent discovery of mutations in the MAX gene (which is part of the 
Myc-Max-Mxd1 network) [40] highlights the value of the rat PHEO cell line PC12, 
which lacks a functional MAX gene, as previously described [85,156]. Also NF1 loss of 
function, found in the MPC cell line used in our assays, has been recently identified as a 
frequent occurrence in sporadic PHEO [114].   
 
Using meta-analysis information from molecular targets of the top drugs identified by our 
screening with gene expression data from human and murine microarrays, we identified 
potential drugs to be used as single drugs or in combination.  
 
There are multiple advantages of screening small molecule libraries of clinically 
approved compounds by repurposing strategies, including the possibility of introducing 
these drugs more rapidly into clinical trials because those drugs have already been used in 
humans for the treatment of other diseases, including other types of cancer.  Drugs that 
received regulatory approval have already proven to be safe and effective for a particular 
disease, and we have historical information regarding the long-term side effects of the 
drug in a large population, which makes repurposing them for other diseases less time-
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consuming. Moreover this approach overcomes several of the economic and technical 
bottlenecks that are inherent to the drug discovery process [157]. Furthermore, the 
repurposing of drugs for new indications, including rare diseases such as PHEO/PGL, is 
gaining momentum in several areas of medicine, as the cost of developing novel chemical 
entities is becoming extremely expensive and time-consuming, often with a questionable 
outcome for the patients [150,158]. 
  
Our primary qHTS screening has identified several compounds with potential activity on 
PHEO/PGL. The repertoire of compounds identified is a potential source available to the 
PHEO/PGL community for further testing, either as single drugs or in combination, either 
with other drugs in our list or with other drugs that have shown activity on PHEO. Of 
particular interest, the antitubulin drugs seem to emerge from our screening as a group of 
drug with a prominent “class effect” on PHEO, with potent activity in the low nanomolar 
range. This suggests that these compounds may have activity as single agents in the 
treatment of metastatic PHEO and possibly PGL.  
 
The secondary screening confirmed activity of several compounds, including the 
antitubulin agents, the HDAC inhibitor SAHA and the topoisomerase inhibitor rubitecan. 
Subsequent analysis combining the results from the screening with data from expression 
microarray assays resulted in the selection of two drugs for combination testing. 
 
The drug combination we chose as an example of using data from the human microarray 
crossed with the cellular network of gene targets of the drug identified by the screening 
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find validation also in the literature. Interestingly, SAHA has been described as a drug 
that induces SDHB protein stabilization and the entry of this protein (although mutated 
but still functional) into the mitochondria [159]. HDAC inhibitors were also found to be 
excellent drugs to increase the uptake of MIBG into PHEO cells [160]. Moreover, the 
anthracycline drug epirubicin has been already used with success in a drug combination 
study for the treatment of malignant PHEO [108]. The combination of topoisomerase and 
HDAC inhibitors has been explored also in other cancer types. Recently, Gray et al. [109] 
described this combination in small cell lung cancer, and other reports validate this 
therapeutic approach. The optimal dosing and timing of administration is still an open 
debate in the literature, and future experiments will need to address this problem in the 
setting of PHEO.  Interestingly, another topoisomerase II inhibitor, doxorubicin, that was 
used as a control in the qHTS screening and in the MTT assays, showed good activity in 
inhibiting the proliferation of PHEO cell lines. In addition, HDAC inhibitors may 
influence the level of acetylation of other non-histone effector molecules, including 
Hsp90 and NF-kB, two other important molecular targets in PHEO. 
 
Of note, our screening was able to identify compounds that we have already explored for 
the potential treatment of PHEO, and so they acted as internal controls of the validity of 
our approach. For example, one of the drugs in the top 50 active compound list was the 
Hsp90 inhibitor 17-AAG, which we investigated in further detail in another study [107]. 
Two other compounds, RTA 402 and parthenolide, have NF-kB as a molecular target, in 
agreement with our recent study on the role of its inhibition as a potential therapeutic 
approach [161]. Interestingly, we also found that several compounds from our screening 
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are in the same class/category of compounds in the mainstay chemotherapy treatment 
(CVD combination), such as microtubule inhibitors, which represent a prominent 
category in our results. 
Another prominent category from our screening was represented by drugs targeting DNA. 
Recent evidence points to a role of DNA methylation in the pathogenesis of SDH mutant 
PHEOs [162], opening the opportunity to use drugs such as the DNA methyltransferase 
inhibitor decitabine (5-aza-2’deoxycytabine), which was one of the hits in our screening. 
In conclusion, we have presented here the adoption of an integrated approach to discover 
potentially clinically useful compounds for the treatment of metastatic PHEO/PGL, and 
we hope that this strategy will help to move forward the field of drug development for 
other orphan diseases. 
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